Monoclonal Antibodies as Promising Therapeutic Agents in the Pharmaceutical Industry and Their Current Challenges. by Ozen, Alara
Monoclonal Antibodies as Promising 
Therapeutic Agents in the Pharmaceutical 












Dissertation submitted in partial fulfilment of the 
requirements for MSc in Pharmaceutical Business & 
Technology (QQI) 
 
Innopharma Labs Faculty of Pharmaceutical Business 











I hereby confirm that this dissertation titled “Monoclonal Antibodies as Promising 
Therapeutic Agents in the Pharmaceutical Industry”, which is presented in partial fulfilment 
of the requirements for the award of the MSc in Pharmaceutical Business and Technology, 
represents my original work, under the supervision of Dr. Munira Derby. 
 
I have appropriately indicated all sources used in the preparation of this study through 




To be filled by the Student: To be filled by the Supervisor: 
  
Signed by: Alara Ozen Signed by: Munira Derby 
  







TABLE OF CONTENTS 
 
STUDENT DECLARATION ________________________________________________ i 
TABLE OF CONTENTS ___________________________________________________ ii 
ACKNOWLEDGEMENTS _________________________________________________ v 
ABSTRACT ____________________________________________________________ vi 
LIST OF FIGURES ______________________________________________________ vii 
LIST OF TABLES _______________________________________________________ ix 
ABBREVIATIONS ______________________________________________________ xi 
CHAPTER I: INTRODUCTION ___________________________________________ 1 
1.1. Background of the Study ____________________________________________ 1 
1.2. Statement of the Problem ____________________________________________ 1 
1.3. Purpose of the Study ________________________________________________ 2 
1.4. Research Objectives ________________________________________________ 2 
1.5. Research Questions ________________________________________________ 3 
1.6. Scope and Limitation of the Study _____________________________________ 3 
1.7. Outline of the Dissertation ___________________________________________ 3 
1.8. Significance of the Study ____________________________________________ 4 
CHAPTER II: LITERATURE REVIEW _____________________________________ 5 
2.1. The Transformation of the Pharmaceuticals from Conventional Medicine into 
Biologics ______________________________________________________________ 5 
2.2. An Overview of Monoclonal Antibody Therapeutics ______________________ 6 
2.3. The Monoclonal Antibody Market _____________________________________ 8 
2.4. The Importance of Monoclonal Antibodies _____________________________ 10 
2.5. Therapeutic Applications of Monoclonal Antibodies _____________________ 11 
2.6. The Discovery of Monoclonal Antibodies by Using Hybridoma Technology __ 11 
2.7. The Progress of the Monoclonal Antibody Therapeutics Over Time _________ 12 
2.7.1. Mouse/Murine Sourced Monoclonal Antibodies _____________________ 12 
2.7.2. Chimeric Monoclonal Antibodies _________________________________ 12 
2.7.3. Humanized Monoclonal Antibodies _______________________________ 13 
2.7.4. Antibody-Drug Conjugates (ADCs) _______________________________ 13 
2.7.5. Fully Human Sourced Monoclonal Antibodies_______________________ 14 
2.7.6. Bispecific Monoclonal Antibodies ________________________________ 16 
2.7. Challenges in the Development and Therapeutic Use of Monoclonal Antibodies 18 
2.7.1. Challenges in Drug Design ______________________________________ 18 
iii 
 
2.7.2. Challenges in Manufacturing ____________________________________ 19 
2.7.3. High Costs as a Consequence and Challenge to Patient Access __________ 20 
2.7.4. Side Effects and Safety Concerns _________________________________ 20 
2.8. The Potential of Monoclonal Antibodies for the treatment of COVID-19 Pandemic
 20 
2.9. Conceptual Framework ____________________________________________ 22 
CHAPTER III: RESEARCH METHODOLOGY AND METHODS _____________ 25 
3.1. Research Philosophy ______________________________________________ 25 
3.2. Research Approach ________________________________________________ 27 
3.3. Methodological Choice ____________________________________________ 28 
3.4. Research Focus ___________________________________________________ 29 
3.5. Research Strategy _________________________________________________ 30 
3.6. Time Horizon ____________________________________________________ 33 
3.7. Ethical Concern __________________________________________________ 34 
CHAPTER IV:  DATA ANALYSIS ________________________________________ 35 
4.1. Demographic Representations of the Respondents _______________________ 35 
4.1.1. The Various Professions of Respondents ___________________________ 35 
4.1.2. The Highest Level of Education of the Respondents __________________ 36 
4.1.3. The Experience with Monoclonal Antibody Therapeutics of the Respondents
 37 
4.2. Analysis of the Objective 1: Assessment of the progression of monoclonal 
antibody generation over time to provide better quality, safety and efficiency of the 
product and advance its therapeutic use. _____________________________________ 38 
4.3. Analysis of the Objective 2: Identification of the current challenges in the 
development and therapeutic use of monoclonal antibody therapeutics. ____________ 40 
4.3.Q1: Do you agree that there are certain factors can influence the development 
process of monoclonal antibodies? _______________________________________ 40 
4.3.Q2. Do you agree or disagree with the statement that monoclonal antibodies are 
overpriced? _________________________________________________________ 42 
4.3.Q3: Is there any governmental funding/support in your country for the use or 
development of biologics/monoclonal antibodies? ___________________________ 43 
4.3.Q4: Do you agree or disagree with the statement that monoclonal antibody 
therapeutics are safe to use? ____________________________________________ 46 
4.3.Q5: Do you agree or disagree with the statement that monoclonal antibodies are 
effective as a newly developed treatment for diseases? _______________________ 47 
4.3.Q6: Do you agree or disagree with the statement that the benefits of monoclonal 
antibodies outweigh the risks? __________________________________________ 48 
iv 
 
4.3.Q7: Do you agree or disagree with the statement that the regulations for 
biologics/monoclonal antibodies in your country are adequate enough to ensure 
product efficacy, quality, and patient safety? _______________________________ 50 
4.3.Q8: Do you agree or disagree with the statement that regulatory differences 
between countries have a significant impact on the development/clinical use of 
monoclonal antibodies? ________________________________________________ 51 
4.4. Analysis of the Objective 3: Analysis of the therapeutic use and challenges of 
monoclonal antibodies from different perspectives of professionals. _______________ 52 
4.4.Q1: Do you agree or disagree with the statement that the use of monoclonal 
antibodies will grow in the future? _______________________________________ 52 
4.4.Q2: I would be very interested to hear from you if you would like to share any 
additional information, thoughts, or experience of working with monoclonal 
antibodies. __________________________________________________________ 53 
4.5. Analysis of the Objective 4: Evaluation of the potential of monoclonal antibodies 
for the treatment of recently emerged COVID-19 pandemic._____________________ 60 
CHAPTER V: DISCUSSION OF THE DATA ANALYSIS _____________________ 61 
CHAPTER VI: CONCLUSIONS AND RECOMMENDATIONS _______________ 65 
6.1. Research Conclusions _______________________________________________ 65 
6.2. Strategic Conclusions ________________________________________________ 65 
6.3. Recommendations __________________________________________________ 66 
7. REFERENCES _______________________________________________________ 68 
8. APPENDICES ________________________________________________________ 75 
Appendix A. The list of monoclonal antibody drugs that approved by major agencies 
from 1986 to 2013 (Strohl, 2014). _________________________________________ 75 
Appendix B. The list of monoclonal antibody drugs that approved by FDA from 2013 to 
2019 (Lu et al., 2020). ___________________________________________________ 78 
Appendix C. A sample of the consent form that was provided to all respondents before 
their participation to the questionnaire. ______________________________________ 83 
Appendix D. A sample of the Section A of the questionnaire that was carried out with 
scientists, medical doctors, regulatory professionals, pharmaceutical/biotechnology 
professionals. __________________________________________________________ 84 
Appendix E. A sample of the Section B of the questionnaire that was carried out with 
scientists. _____________________________________________________________ 85 
Appendix F. A sample of the Section B of the questionnaire that was carried out with 
medical doctors. _______________________________________________________ 89 
Appendix G. A sample of the Section B of the questionnaire that was carried out with 
regulatory professionals. _________________________________________________ 92 
Appendix H. A sample of the Section B of the questionnaire that was carried out with 





I would like to express my great appreciation to Dr. Munira Derby for her precious guidance, 
valuable encouragement, useful recommendations, technical support, and patience 
throughout the dissertation process. 
 
My sincere gratitude to all of the participants of the questionnaire as part of this research for 
sharing their valuable knowledge and opinion, which made a significant contribution to the 
study. Special thanks to Assoc. Prof. Dr. Nazli Keskin Toklu for her motivational and 
supportive attitude since the very first time we met. 
 
Finally, I am extremely grateful to my family for their immense support and encouragement 






Monoclonal antibody discovery and their use as therapeutic agents have made a revolutionary 
transformation in the research focus of the pharmaceutical industry which reflected to market 
growth with their promising profile for considerably severe diseases which are lacking in a 
complete treatment such as cancer and autoimmune disorders. However, their biochemical 
aspects bring various complexity and challenges in the development and use. This study 
evaluates the impact that monoclonal antibody therapeutics have made on the pharmaceutical 
industry, identifies the success in the generation of different monoclonal antibody formats 
over time, finds out the current bottlenecks within the development and therapeutic use of 
monoclonal antibodies, and assesses their potential as therapeutic agents for currently 
untreatable diseases, with a special emphasis on their promising implementation into 
COVID-19. The study comprises qualitative and quantitative approach and was carried out 
with a group of 98 professionals that consisted of scientists, medical doctors, regulatory 
professionals, pharmaceutical/biotechnology professionals. Findings show that the most 
challenging factor in the development of monoclonal antibody therapeutics is the drug design 
and formulation, while high costs was identified as the most challenging factor for their use. 
Even though the bottlenecks in the development and use of monoclonal antibodies, 
challenges are considered manageable in the close future as a consequence of the growing 
interest in improving monoclonal antibodies, and global focus for their use against COVID-
19, as well as patent expirations which will lead to biosimilar alternatives. 
 
 
Key words: Antibodies; monoclonal antibodies; chimerization technology; hybridoma 
technology; cytokines; COVID-19. 
vii 
 
LIST OF FIGURES 
  
Fig. 2.1. The degree of complexity between conventional treatment method, biological 
product, and monoclonal antibody structure (Mabxience, 2019). ......................................... 6 
 
Fig. 2.2. The cytokine types that cause autoimmune disorders (Luo et al., 2020). ............... 7 
 
Fig. 2.3. Demonstration of cytokine storms (Luo et al., 2020). ............................................. 7 
 
Fig. 2.4. The market growth of monoclonal antibody therapeutics and their estimated 
annual sales by 2024 (BioPharma, 2019). .............................................................................. 9 
 
Fig. 2.5. The best-selling 10 monoclonal antibody therapeutics in 2018 (BioPharma, 2019).
 ................................................................................................................................................ 9 
 
Fig. 2.6. The evolution of monoclonal antibodies from mouse-derived to fully human-
sourced (Catapano and Papadopoulos, 2013). ..................................................................... 15 
 
Fig. 2.7. The steps of fully human monoclonal antibody production by using transgenic 
mice and hybridoma technology developed by Amgen (Foltz et al., 2013). ....................... 16 
 
Fig. 2.8. Catumaxomab molecule interacting with EpCAM and CD3 (Sedykh et al., 2018).
 .............................................................................................................................................. 17 
 
Fig. 2.9. The growth of the market value of monoclonal antibody drugs between 1975-2019 
(Lu et al., 2020). ................................................................................................................... 18 
 
Fig. 2.10. The conceptual framework of the promising aspects of the monoclonal 
antibodies. ............................................................................................................................ 23 
 
Fig. 2.11. The conceptual framework of the challenges in the development and therapeutic 
use of monoclonal antibodies. .............................................................................................. 24 
 
Fig. 3.1. The connection between beliefs and assumptions, research philosophies, and 
research design (Saunders et al., 2019). ............................................................................... 25 
 
Fig. 3.2. Methodological choices and research design types (Saunders et al., 2019). ......... 28 
 
Fig. 3.3. Research onion (Saunders et al., 2019), and the followed techniques for this study.
 .............................................................................................................................................. 33 
 
Fig. 4.1. The bar chart representing the number of the participants according to their 
professions. .......................................................................................................................... 35 
 
Fig. 4.2. The representation of the highest level of education attained by the respondents 




Fig. 4.3. The demonstration of the respondents according to their experience of working 
with monoclonal antibodies. ................................................................................................ 38 
 
Fig 4.4. The representation of globally marketed monoclonal antibody therapeutics between 
2010-2014 and 2015-2019 according to their antibody format (Strohl, 2014; Lu et al., 
2020). ................................................................................................................................... 39 
 
Fig. 4.5. The demonstration of the viewpoints of the scientists and 
pharmaceutical/biotechnology professionals for the factors that can influence the 
development of monoclonal antibodies. .............................................................................. 41 
 
Fig. 4.6. The demonstration of the points of views of the total respondents to the question 
whether they find monoclonal antibodies overpriced. ......................................................... 43 
 
Fig. 4.7. The representation of the outcomes from the respondents questioned whether any 
governmental funding/support exists in their country for the use or development of 
biologics/monoclonal antibodies. ......................................................................................... 44 
 
Fig. 4.8. The representation of the perspective of medical doctors whether they agree that 
monoclonal antibodies are safe to use. ................................................................................. 46 
 
Fig. 4.9. The representation of the perception of scientists and medical doctors whether 
they find monoclonal antibodies effective as a newly developed treatment for diseases. ... 48 
 
Fig. 4.10. The representation of the perception of scientists and medical doctors on the 
benefit/risk balance of monoclonal antibodies. .................................................................... 49 
 
Fig. 4.11. The representation of the point of views of the regulatory professionals on their 
agreement or disagreement that the regulations for biologics/monoclonal antibodies in their 
country are adequate enough to ensure product efficacy, quality, and patient safety. ......... 50 
 
Fig. 4.12. The representation of the perceptions of the regulatory professionals on their 
agreement or disagreement that regulatory differences between countries have a significant 
impact on the development/clinical use of monoclonal antibodies. .................................... 51 
 
Fig. 4.13. The representation of the perceptives of the respondents on their agreement or 
disagreement that the use of monoclonal antibodies will grow in the future. ..................... 52 
 
Fig. 4.14. The distribution of the positive perceptions and concerns/challenges about 




LIST OF TABLES 
Table 4.1. The representation of the number of the participants according to their 
professions. .......................................................................................................................... 35 
 
Table 4.2. The distribution of the highest level of education attained by the respondents 
according to their professions. ............................................................................................. 36 
 
Table 4.3. The respondents according to their experience of working with monoclonal 
antibodies. ............................................................................................................................ 37 
 
Table 4.4. The distribution of globally marketed monoclonal antibody therapeutics 
according to their antibody format. ...................................................................................... 39 
 
Table 4.5. The point of view of the scientists and pharmaceutical/biotechnology 
professionals for the factors that can influence the development of monoclonal antibodies.
 .............................................................................................................................................. 40 
 
Table 4.6. The points of views of the total respondents to the question whether they find 
monoclonal antibodies overpriced. ...................................................................................... 43 
 
Table 4.7. The outcomes from the respondents questioned whether any governmental 
funding/support exists in their country for the use or development of biologics/monoclonal 
antibodies. ............................................................................................................................ 44 
 
Table 4.8. The countries and the type of the governmental funding/support for the use 
and development of monoclonal antibodies, according to the answers obtained from the 
questionnaire. ...................................................................................................................... 45 
 
Table 4.9. The perspective of medical doctors whether they agree that monoclonal 
antibodies are safe to use...................................................................................................... 46 
 
Table 4.10. The perception of scientists and medical doctors whether they find monoclonal 
antibodies effective as a newly developed treatment for diseases. ...................................... 47 
 
Table 4.11. The responses of scientists and medical doctors whether they agree to the 
statement that benefits of monoclonal antibodies outweight the risks. ................................ 49 
 
Table 4.12. The point of views of the regulatory professionals on their agreement or 
disagreement that the regulations for biologics/monoclonal antibodies in their country are 
adequate enough to ensure product efficacy, quality, and patient safety. ............................ 50 
 
Table 4.13. The perceptions of the regulatory professionals on their agreement or 
disagreement that regulatory differences between countries have a significant impact on the 
development/clinical use of monoclonal antibodies. ........................................................... 51 
 
Table 4.14. The perceptions of respondents on their agreement or disagreement that the use 




Table 4.15. The distribution of the positive perceptions and concerns/challenges about 
monoclonal antibodies defined by the professionals from the associated disciplines. ........ 53 
 
Table 4.16. The positive perceptions and concerns/challenges about monoclonal antibodies 
according to scientists. ......................................................................................................... 55 
 
Table 4.17. The positive perceptions about monoclonal antibodies according to medical 
doctors. ................................................................................................................................. 56 
 
Table 4.18. The positive perceptions and concerns/challenges about monoclonal antibodies 
according to regulatory professionals. ................................................................................. 57 
 
Table 4.19. The positive perceptions and concerns/challenges about monoclonal antibodies 





ADCs Antibody-drug conjugates 
AML Acute myeloid leukemia 
Anti-IL-6R Anti-interleukin-6 receptor 
BARDA Biomedical Advanced Research and Development Authority 
BIRAC Biotechnology Industry Research Assistance Council 
CD19 Cluster of differentiation 19 
CD20 Cluster of differentiation 20 
CD3 Cluster of differentiation 3  
CDSCO Central Drugs Standard Control Organisation 
COVID-19 Coronavirus disease 19 
CRUK Cancer Research UK 
DBT Department of Biotechnology 
DFG German Research Foundation 
DST The Department of Science and Technology 
EpCAM Epithelial cell adhesion molecule 
FDA Food and Drug Administration 
GMP Good Manufacturing Practice 
HGS Human Genome Sciences 
ICMR Indian Council of Medical Research 
IDA Industrial Development Authority 
IL-6 Interleukin 6 
NHPs Non-human primates 
NIH National Institutes of Health 
RA rheumatoid arthritis 
SARS-Cov2 Severe acute respiratory syndrome coronavirus 2 
SFI Science Foundation Ireland 
SGK Turkish Social Security Agency  
TNF tumour necrosis factor 
TNF- α tumour necrosis factor alpha 
TUBITAK The Scientific and Technological Research Council of Turkey 
TUSEB Health Institutes of Turkey 
xii 
 
UCD  University College Dublin 




CHAPTER I: INTRODUCTION 
1.1. Background of the Study  
Monoclonal antibodies are considered very likely to be hope for rapidly growing 
severe diseases that for the most part end up with lethality. According to Ipsos, a 
multinational market research company, the most common cause of death in 2019 in global 
was cardiovascular diseases (32%), followed by cancer (24%), neurological disorders (9%), 
lower respiratory infections such as pneumonia (6%), chronic respiratory diseases such as 
asthma (5%), diabetes and kidney diseases (5%) of which the use of monoclonal antibody 
therapeutics is emerging for their treatment (Nissim and Chernajovsky, 2008; Ipsos, 2020). 
Additionally, there are ongoing pre-clinical and clinical studies about the use of monoclonal 
antibodies for the COVID-19 pandemic that arose in Wuhan, China in December 2019 and 
hit over 24 million people in global, resulting in over 833,000 death by August 27, 2020. 
Because of the high market demand and promising aspects, many of the leading 
pharmaceutical companies have begun to invest in the research and development of 
monoclonal antibody therapeutics, launched new antibody generation techniques for a 
stronger efficacy, better quality and safety of the product, also to expand their use to make 
them available for the treatment of more diseases with no cure. The use of monoclonal 
antibody therapeutics is rapidly growing in global and believed to be the future of the 
pharmaceutical industry (Lu et al., 2020). 
1.2. Statement of the Problem  
The collaboration between scientists, medical doctors, and the pharmaceutical 
industry has a common purpose: to provide the safest, most efficient, highest of quality, and 
cost-effective treatment in the fastest time to make the treatment accessible to every patient 
in need, aiming to improve human health and life quality of patients. However, the 
circumstances may not be as ideal as stated, thus, it may not always be possible to achieve 
all of those aspects at the same time. For instance, even though monoclonal antibody 
therapeutics has made an impressive impact on the pharmaceutical industry, there are still 




To be more specific, the technology and methods utilised to generate monoclonal 
antibodies are highly expensive, time-consuming, and difficult to achieve. Because the 
therapeutic use of monoclonal antibodies is relatively new and still continues to be improved, 
a huge investment on research and development is needed to overcome their challenging 
aspects (Sewell et al., 2017; Almagro et al., 2018). 
Research and development studies cost billions for many biologics/monoclonal 
antibody therapeutics, which constitutes the main challenge. In addition to that, their 
production expenses are also high as they are manufactured in small amounts by using 
advanced biotechnology techniques. Along with their high expenses in research and 
development, and manufacturing, another element that increases the cost of monoclonal 
antibody therapeutics is that very less number of approved biosimilar alternatives (Wu et al., 
2018). 
 
1.3. Purpose of the Study 
 The purpose of this study is to evaluate the therapeutic use and the potential of 
monoclonal antibodies as an emerging technology in the pharmaceutical industry, and identify 
their current challenges in the development and therapeutics use considering the perspectives 
of scientists, medical doctors and pharmaceutical/biotechnology professionals. 
1.4. Research Objectives 
 Objective 1: Assessment of the progression of monoclonal antibody generation over 
time to provide better quality, safety and efficiency of the product and advance its therapeutic 
use. 
 Objective 2: Identification of the current challenges in the development and 
therapeutic use of monoclonal antibody therapeutics. 
 Objective 3: Analysis of the therapeutic use and challenges of monoclonal antibodies 
from different perspectives of professionals. 
 Objective 4: Evaluation of the potential of monoclonal antibodies for the treatment of 




1.5. Research Questions 
• How did monoclonal antibody therapeutics impact the market profile and 
investments of the pharmaceutical companies? 
• How have monoclonal antibody generation been improved since the discovery to 
assure the quality, safety and efficiency of the product and advance the 
therapeutic use? 
• What are the challenges in the development of monoclonal antibody 
therapeutics? 
• What are the viewpoints of professionals with different scientific backgrounds 
about monoclonal antibody therapeutics in terms of their use and challenges? 
• How urgent is the need of treatments of the diseases in which monoclonal 
antibodies show promise? 
1.6.  Scope and Limitation of the Study 
This study covers the impact of monoclonal antibodies on the pharmaceutical market, 
the progress of monoclonal antibody types over time, the challenges in the development and 
therapeutic use of monoclonal antibodies from different perspectives of scientists, medical 
doctors, regulatory professionals, and pharmaceutical/biotechnology professionals, and their 
potential for the treatment of Coronavirus disease 19 (COVID-19). 
The scope of this study does not cover:  
• The use of monoclonal antibodies for diagnostic purposes. 
• The regulations for biological products/biosimilars. 
1.7. Outline of the Dissertation 
The dissertation comprises of six chapters which initiates with a brief introduction in 
Chapter I, where the background of the study is explained, the problem is explained, purpose 
of the study is provided, research objectives and questions are presented, along with the scope 
and delimitation of the study and the significance. 
Chapter II comprises of literature review, which begins with a short introduction 
about the transformation of the pharmaceuticals into biologics, continues with the 
monoclonal antibody market and further continues with monoclonal antibodies. Their 
therapeutic applications, importance, discovery, progress over time, challenges in the 
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development and therapeutic use and ends with their potential implementation into COVID-
19. 
Research methodology is presented in Chapter III, which includes the explanation of 
the research philosophies and further strategies that this study followed. The data obtained 
from primary and secondary research are presented under Chapter IV and discussed in 
Chapter V. 
According to the obtained results, the findings were concluded, and possible 
recommendations were presented in Chapter VI. 
1.8. Significance of the Study 
The identification of the difficulties in the development and therapeutic use of 
monoclonal antibodies and focusing on the most impactful element on the process are the 
first steps to overcome these problems. 
The considerations from the experts in the monoclonal antibody field plays a crucial 
role for the biotechnology industry as the problem can be effectively solved with the 
collaboration between scientists; who are keys in research and development of therapeutics 
and experts in understanding of disease mechanisms, medical doctors; who witness to the 
clinical use of drugs in the first place, which makes them well aware of any possible 
complication during the treatment, and the pharmaceutical industry; in which their progress 
depends on the outcomes of the patients, scientists, and health care professionals primarily. 
Considering that, this study provides specific attention to the perspectives of 
scientific, medical, regulatory, pharmaceutical/biopharmaceutical professionals about the 
challenges in the development and therapeutic use concerning monoclonal antibody 
therapeutics. Additionally, the promising aspects of monoclonal antibodies in the 
pharmaceutical industry, and their potential implementation into the recently emerged 
COVID-19 pandemic is also included in this study. While the treatment for the pandemic is 
urgently needed in the world, the potential of monoclonal antibodies as possible cure to 




CHAPTER II: LITERATURE REVIEW 
 
2.1. The Transformation of the Pharmaceuticals from Conventional Medicine into 
Biologics 
The pharmaceuticals have been reshaped over the past two decades with the launch 
of protein-based medicines, also referred as “biologics”. They can consist of proteins, nucleic 
acids, sugars, also combination of these biological materials, or even living entities such as 
cells and tissues (Shepard et al., 2017). With the advancements in the genetic engineering 
techniques, biological products can include gene therapy, recombinant proteins, hormones, 
or vaccines and blood components such as antibodies. They are manufactured by isolating 
from the natural sources – human, animal, or microorganism, or by using biotechnology 
techniques and other cutting-edge technologies which shows promise to overcome medical 
needs that currently have no solution (FDA, 2019). 
Contrary to conventional medicines, also referred as small molecules, which are 
chemically manufactured with well-known structure, biological products are complex 
molecules that are not certainly identified and characterized. They are susceptible to heat and 
carry the risk of microbial contamination (FDA, 2019). 
Monoclonal antibody therapeutics constitutes the majority of biological products 
(Shepard et al., 2017). They have even more complex molecular structure than many other 
biologics, therefore, they are produced using the most advanced technologies (Mabxience, 
2019). 
Figure 2.1. shows the degree of complexity between small molecule as conventional 





Fig. 2.1. The degree of complexity between conventional treatment method, biological 
product, and monoclonal antibody structure (Mabxience, 2019). 
 
2.2. An Overview of Monoclonal Antibody Therapeutics 
Monoclonal antibodies have a wide range of therapeutic applications varying from 
different types of cancer disease and autoimmune disorders such as rheumatoid arthritis, 
lymphoma, Crohn’s disease, psoriasis, as well as organ transplantation (Da et al., 2017; 
Mabxience, 2019). 
Cytokines are proteins that are responsible for activating the human immune system 
in the event of infection. However, the overproduction of these molecules results to cytokine 
storms which are an important risk factor of autoimmune disorders (NRAS, 2020). There are 
more than 100 immune-mediated diseases of which 7% of the global population is affected 
and statistics show that 75% of the patients are women and 25% of them men (AARDA, 
2016; OWH, 2017). 
Figure 2.2. shows the cytokine types (interleukine-1, interleukine-6, interleukine-17, 
tumour necrosis factor-α) that cause autoimmune disorders. Demonstration of cytokine 






Fig. 2.2. The cytokine types that cause autoimmune disorders (Luo et al., 2020). 
 
Fig. 2.3. Demonstration of cytokine storms (Luo et al., 2020). 
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Monoclonal antibodies act against these cytokines to reduce their existence and 
activity in the body by neutralizing cytokines directly, or by binding their receptors which 
would block the interaction between them (NRAS, 2020). These cytokine blocking 
monoclonal antibodies have made a revolution in therapeutic approaches, together with 
bringing quite considerable profits to the pharmaceutical industry. Remicade (infliximab), 
Simponi (golimumab), Cimzia (certolizumab pegol), and Humira (adalimumab) are 
examples to approved monoclonal antibodies that inhibit the effect of cytokines (Shepard et 
al., 2017; NRAS, 2020). 
Additionally, the studies on cytokine blocking monoclonal antibodies have also 
gained pace because of COVID-19 as cytokine storms in exceeding amounts were detected 
in patients with severe conditions (Luo et al., 2020). 
2.3. The Monoclonal Antibody Market 
Over the past 30 years, monoclonal antibody-based drugs have switched from being 
a research target to a developed technology and taken place in clinical research to even 
commercialization. Throughout the last 5 years, monoclonal antibodies have been the fastest 
growing segment in global biopharmaceutical market and kept their blockbusting place in 
the pharmaceutical market. (Lu et al., 2020). 
In the worldwide best-selling drug portfolio of 2018, 8 drugs out of 10 were biological 
medicines. In the same year, the global market capitalization of monoclonal antibodies was 
at US$115.2 billion, while the forecast for 2019 was $158 billion and it is expected to grow 
up to $300 billion by 2025. Therefore, the market for therapeutic antibody medicines has 
massively grown as new medicines have been authorized in the treatment of several human 
ailments, such as autoimmune, infectious, metabolic diseases as well as many cancer types. 
There have been 182 monoclonal antibody-based drugs proceeding with the Phase III clinical 
trials throughout the world since April 2019. The number of US FDA approved therapeutic 
mAbs was 79 as of the end of 2019, and yet it is expected to increase massively (RIC, 2019; 
Lu et al., 2020). 
The major pharmaceutical companies leading the monoclonal antibody market are 
followed as Merck, Roche, AbbVie, Johnson & Johnson, Novartis, and Amgen. Humira by 
AbbVie, Avastin and Rituxan by Roche, Keytruda by Merck, Remicade and Stelara by 
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Johnson & Johnson, Enbrel by Amgen were the best-selling eight monoclonal antibody drugs 
in 2018 that made US$64 billion together with a collective 55,6% share in global market 
(RIC, 2019). 
The current and estimated market growth of monoclonal antibodies are shown in 
Figure 2.4. Additionally, the best-selling 10 monoclonal antibody therapeutics in 2018 are 
shown in Figure 2.5.  
 
Fig. 2.4. The market growth of monoclonal antibody therapeutics and their estimated 
annual sales by 2024 (BioPharma, 2019). 
 
 
Fig. 2.5. The best-selling 10 monoclonal antibody therapeutics in 2018 (BioPharma, 2019). 
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2.4. The Importance of Monoclonal Antibodies 
Antibodies are the fundamental functional unit of the humoral immune system, as 
they are produced in order to neutralize toxins, inhibit the activity of foreign materials which 
are referred as antigens (Hanack et al., 2016; Mahmuda et al., 2017). They are synthesized 
and secreted by B-cells as an immune response against antigens such as fungi, bacteria, 
viruses, toxins, etc (Stewart, 2004; Forthal, 2014; Zahavi et al., 2018) and can be categorized 
as polyclonal and monoclonal. Monoclonal antibodies are synthesized in laboratory 
conditions by replicas originated from a single parent B-cell (NIH, 2020). They show a robust 
affinity to one particular region of an antigen that antibodies bind to. Polyclonal antibodies 
on the other hand, are generated by various clones of B-cells and can bind to diverse regions 
in the same antigen (NICB, 2016; Hanack et al., 2016; Panawala, 2017; Sathyajith, 2020). 
The main aspects of monoclonal antibodies that make them unique are: 
• Batch-to-batch uniformity, 
• Low background reactivity, 
• Uniqueness to a single epitope,  
• Potential to be produced identically and in large amounts at a time, 
• Providing higher accuracy in assays that require quantification of the protein 
levels. 
These aspects reduce the risk of cross-reactivity and allow monoclonal antibodies to 
have a highly homogenous population. Thus, they provide better results in experiments and 
can be used to target specific antigens. Being able to be produced in larger quantities is 
another advantage for diagnostic manufacturing and therapeutic drug development 
(Panawala, 2017). 
Before the discovery of hybridoma technology, scientists were dependent on 
polyclonal antibodies for experiments concerning the particular proteins of interest within 
complex biological environments to be identified and quantified. However, even though 
polyclonal antibodies have their individual set of advantages, they are not convenient to be 
applied for in vivo experiments or therapeutics because they cannot provide batch-to-batch 
consistency and they possess high amount of background reactivity (Zaroff and Tan, 2019). 
Monoclonal antibodies are a much better solution for the therapeutic drug development as it 
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requires large quantities of identical antibody unique to one single epitope. For common 
research purposes instead, polyclonal antibodies are usually preferred. To give an example, 
when used for affinity purification of serum against small antigen targets, the benefits of 
polyclonal antibodies outweigh what monoclonal antibodies provide (Panawala, 2017). 
2.5. Therapeutic Applications of Monoclonal Antibodies 
The highly specific identification and attachment ability of monoclonal antibodies for 
many molecules has been broadly used for the detection of cytokines, vitamins, allergens, 
hormones, many tumour markers in the field of diagnosis, and an extensive variety of 
indicators linked with many diseases, as well as microbial infections (Da et al., 2017). These 
aspects allowed monoclonal antibodies to be used for clinical diagnosis, therapeutic targets, 
delivery of other drugs, and identification of markers. 
Medical application of monoclonal antibodies has turned out to be a crucial element 
of therapies in numerous diseases including cardiovascular, autoimmune, oncology, 
infectious diseases as well as organ transplantation (Nissim and Chernajovsky, 2008). In 
addition to these, they can be used for osteoporosis, age-dependent macular degeneration, 
multiple sclerosis, asthma, too. The investigation of possible use of monoclonal antibodies 
in the treatment of metabolic diseases, central nervous system disorders and the prevention 
of migraines is ongoing (Da et al., 2017). 
2.6. The Discovery of Monoclonal Antibodies by Using Hybridoma Technology 
During the 1890s, Emil von Behring and Kitasato Shibasaburo noticed that animals 
which have never been infected with diseases such as diphtheria or tetanus before, could gain 
immunity by blood taken from animals which formerly exposed to such diseases. Subsequent 
to that, it was discovered by Paul Ehrlich that the defence in blood sourced by antibodies 
(Kaufmann, 2017). 
Along with these findings, antibodies have been considered as potential magic bullets 
for human health and thus scientists focused on possible ways to separate and purify specific 
antibodies from the billions generated by the immune system. The first study on the 
production of mouse-sourced monoclonal antibodies was completed with hybridoma 
technology by Georges Köhler and Cesar Milstein in 1975 based at the Laboratory of 
Molecular Biology in Cambridge, UK (Nissim and Chernajovsky, 2008). The discovery of 
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hybridoma technology made Milstein and Köhler share the Nobel Prize for Medicine or 
Physiology together with Niels Kaj Jerne in 1984 for “theories concerning the specificity 
in development and control of the immune system and discovery of the principle for 
production of monoclonal antibodies” (Ribatti, 2014). In vivo scientific research met with 
monoclonal antibodies with the discovery of hybridoma technology, and this breakthrough 
gave rise to some of the biggest scientific revolutions of the 21st century such as in vivo 
diagnostics, monoclonal antibody therapeutics and antibody-drug conjugates (ADCs) (Zaroff 
and Tan, 2019). 
Hybridomas consist of a short-lived antibody generating B-cell fused with an 
immortal myeloma cell. This form of fused cells allows one specific monoclonal antibody 
type to be constitutively expressed in a large quantity. In addition to that, preferred 
hybridoma cell lines can also be cryopreserved to keep monoclonal antibody production 
long-lasting. For this reason, scientists most of the time prefer producing hybridomas on top 
of other monoclonal antibody production techniques with the intention of maintaining a 
convenient and continuous supply of crucial monoclonal antibodies (Zaroff and Tan, 2019). 
2.7. The Progress of the Monoclonal Antibody Therapeutics Over Time 
2.7.1. Mouse/Murine Sourced Monoclonal Antibodies 
The first monoclonal antibody-based therapy was sourced by murine monoclonal 
antibodies, later by murine-human chimeras, followed by humanized and soon after human 
monoclonal antibodies. Each of these monoclonal antibody types have been accepted by 
Food and Drug Administration (FDA) as well as by other international agencies (Ribatti, 
2014). 
The first FDA approved monoclonal antibody drug for human use was Orthoclone 
OKT3 (muromonab), marketed by Ortho Biotech (J&J), a murine-sourced anti-CD3 
monoclonal antibody, to be used in the treatment of organ transplant rejection (Ribatti, 2014). 
The drug was approved in 1986 when murine monoclonal antibodies were in clinical 
development. 
2.7.2. Chimeric Monoclonal Antibodies 
Even though the discovery of murine-sourced monoclonal antibodies are considered 
as a revolution for the pharmaceutical industry, they are frequently linked with allergic 
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responses, and the production of anti-drug antibodies that inhibit the therapeutic 
consequences of the drug. To deal with such adverse reactions, chimerization technology was 
developed by using genetic engineering tools as the complete antigen-specific domain of a 
mouse antibody was grafted on top of the constant domains of a human antibody (Ribatti, 
2014). 
Rituxan (rituximab), a mouse-human chimeric monoclonal antibody developed by 
Roche and approved by FDA in 1997, was the first monoclonal antibody to be used in the 
treatment of malignancy. It works against CD20 receptor expressed on the surface of B cells 
and promotes cell death in conditions such as lymphoma. Even though rituximab was initially 
developed for the treatment of lymphoma, it is progressively used for autoimmune diseases 
(Randall, 2016). 
2.7.3. Humanized Monoclonal Antibodies 
Zinbryta (daclizumab) by Biogen and AbbVie was the first humanized monoclonal 
antibody to be used against multiple sclerosis, approved by FDA in 1997. Followed by, 
Zenapax (daclizumab) by Roche was developed as a biosimilar to be used for organ 
transplant rejection (Reichert et al., 2005). However, both of the drugs were withdrawn with 
the request of market authorization holders in 2009 and 2018 (EMA, 2009; FDA, 2018). 
Roche stated that discontinuation request was not due to any safety issue but to the decreasing 
market demand and the availability of alternative treatments in 2009. Contrary to that, Biogen 
and AbbVie had concerns about the risk/benefit balance of the drug after reports of 
meningoencephalitis in daclizumab use and 3 out of 12 cases were fatal (Williams and 
Chataway, 2019). Meningoencephalitis is a neurological disorder that brain and its adjacent 
protective membranes are inflamed because of viruses, bacteria, fungi, or other pathogens 
(Olsen et al., 2015).  
The discovery of daclizumab showed that humanization of monoclonal antibodies 
was possible, yet its toxicity was an indication that humanization technology was not the 
ultimate solution to ensure the safety of monoclonal antibody therapeutics. 
2.7.4. Antibody-Drug Conjugates (ADCs) 
When monoclonal antibody therapeutics are used in combination with other 
molecules such as protein toxins, immunomodulators, radionuclides, etc. in order to increase 
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or decrease the cytotoxicity depending on the disease mechanism, they are called antibody-
drug conjugates (ADCs) (Zhao et al., 2020).  
The first FDA approved ADC was Mylotarg (gemtuzumab ozogamicin), an example 
of a monoclonal antibody combined with an immunotoxin, by Pfizer in 2000 to be used 
against acute myeloid leukemia (AML) disease. It was voluntarily discontinued in the United 
States after being marketed for 10 years. However, due to the vital unmet need of AML 
treatment it was introduced in the market again in 2018 with altered dosage and 
administration (Ribatti, 2014; Almagro et al., 2018).  
2.7.5. Fully Human Sourced Monoclonal Antibodies 
Monoclonal antibodies have been continued to be the focus for scientists and 
developed with even more human-like constant domains (Almagro et al., 2018). Along with 
improved techniques, Humira (adalimumab) by Abbott was the first fully human monoclonal 
antibody approved by FDA in 2002. The name stands for "human monoclonal antibody in 
rheumatoid arthritis" (Lu et al., 2020). The drug was obtained with phage display technology 
and turn out to be the most successful monoclonal antibody on the market, considering the 
effectiveness of the product. Currently, it is used for a broad range of autoimmune diseases 
such as psoriasis, rheumatoid arthritis, uveitis, Crohn’s disease, ulcerative colitis, 
hidradenitis suppurativa, juvenile arthritis, psoriatic arthritis, Behçet’s syndrome and axial 
spondyloarthritis (Reimold, 2012; Kaplon and Reichert, 2019). 
The Figure 2.6. shows the progress that have been made to increase safety of 
monoclonal antibodies by generating more human-like monoclonal antibodies. 
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Fig. 2.6. The evolution of monoclonal antibodies from mouse-derived to fully human-
sourced (Catapano and Papadopoulos, 2013). 
Soon after, transgenic mice technology was developed for the production of fully 
human immunoglobulins. To achieve this, their own genes responsible for producing murine 
antibodies were inactivated and replaced with human antibody producing genes, followed by 
the traditional hybridoma technology to fuse antibody-producing mice cells with immortal 
cells to achieve continuous production. Transgenic technology result to better 
pharmacodynamic and pharmacokinetic aspects of monoclonal antibody therapeutics. 
Vectibix (panitumumab) by Amgen was the first completely human monoclonal antibody 
drug produced by using transgenic mice technology against colorectal cancer, FDA approved 
in 2006 (Ribatti, 2014; Almagro et al., 2018; Lu et al., 2020). The transgenic mice technology 
developed by Amgen is explained in Figure 2.7. 
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Fig. 2.7. The steps of fully human monoclonal antibody production by using transgenic 
mice and hybridoma technology developed by Amgen (Foltz et al., 2013). 
 
2.7.6. Bispecific Monoclonal Antibodies 
The advancements in the recombinant technology allowed monoclonal antibodies to 
evolve into bispecific antibodies. They provide two target specificities in a single antibody 
as they have two different binding domains within the same form, thus, increase the 
effectiveness compared to the combination of two single antibodies (Ribatti, 2014; Almagro 
et al., 2018). 
Three bispecific monoclonal antibodies, Removab (catumaxomab) by Neovii Biotech 
in 2009 in Europe only, Blincyto (blinatumomab) by Amgen in 2014, and Hemlibra 
(emicizumab) by Roche in 2017 were approved for medical use (Almagro et al., 2018; 
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Sedykh et al., 2018; Lu et al., 2020). However, Removab was requested to be withdrawn by 
the market holder due to commercial reasons in 2017 (Lu et al., 2020). 
Removab and Blincyto both interact with cluster of differentiation 3 (CD3) on T-cells 
with one chain of the molecule, while other chain targets cancer cells generating epithelial 
cell adhesion molecule (EpCAM) or cluster of differentiation 19 (CD19), individually. 
Simultaneous interaction of bispecific antibodies with CD3 and EpCAM or CD19 makes 
cancer cells and T cells come closer resulting with very effective inactivation of the cancer 
cells (Almagro et al., 2018). 
Figure 2.8. shows catumaxomab interacting with EpCAM and CD3 as an example of 
how bispecifics work simultaneously. 
 
Fig. 2.8. Catumaxomab molecule interacting with EpCAM and CD3 (Sedykh et al., 2018). 
Humanization of monoclonal antibodies, ADCs, phage-displayed libraries, the 
development of transgenic animals, as well as bispecific antibodies were among the emerged 
antibody technologies during the last 30 years (Almagro et al., 2018). 
The growth of the market value of monoclonal antibody drugs between the years 




Fig. 2.9. The growth of the market value of monoclonal antibody drugs between 
1975-2019 (Lu et al., 2020). 
The full list of monoclonal antibody drugs that approved by major agencies and their 
sources of antigen-specific variable domains can be found in Appendix A and Appendix B 
(Strohl, 2014; Lu et al., 2020). 
2.7. Challenges in the Development and Therapeutic Use of Monoclonal Antibodies 
2.7.1. Challenges in Drug Design 
Use of animals is the most prominent challenge in the development of monoclonal 
antibodies. Understanding of immune response to biological medicinal products is a 
complicated process that depends on different variables which have not been completely 
clarified yet. Some of these factors can be uncertainties about the product, disease 
mechanism, animal species, or factors that are particular to patients (TreDenick, 2018). 
To give an example, in the pre-clinical safety and toxicology tests, non-human 
primates (NHPs) are frequently used as they are one of the few species that monoclonal 
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antibodies show high pharmacological performance. Nevertheless, primate and human 
physiology can have vital differences resulting in concerns about safety and efficacy of the 
drug. The ongoing studies in bioinformatics aim to improve human safety predictions by 
using several algorithms to compare gene sequences of different species (Sewell et al., 2017; 
TreDenick, 2018). This approach will eventually minimize the animal use and reduce the 
challenge of translation between species in near future. 
2.7.2. Challenges in Manufacturing 
Monoclonal antibody therapeutics are excellent molecules by means of highly 
specific targeting, and show promise for the treatments of widespread diseases with no cure. 
However, they are complex molecules which can also have undesired biophysical assets that 
negatively impact on their manufacturing process (TreDenick, 2018). Some of these concerns 
can be: 
• Insufficient expression, 
• Instability, 
• Random cross-reactivity, 
• Weak pharmacokinetic activities  
Monoclonal antibodies can either be administered as intravenous or subcutaneous. 
The average needed amount of monoclonal antibodies are ranging between a few hundred 
milligrams and 1 gram per dose to attain the desired concentration. According to FDA, the 
dose of a subcutaneous injection must not exceed 1,5 millilitre (mL). Thus, monoclonal 
antibody therapeutics are generally formulated denser than 100 mg/mL, which are extremely 
high levels of concentration that often lead to complexities in the production. Due to lack of 
space, highly dense environments in which monoclonal antibodies exist may cause to 
generation of reversible protein aggregates that increases the viscosity, and brings challenges 
at the filling stage (TreDenick, 2018; Razzaqi et al., 2019). 
On the other hand, sustaining the required product stability within a highly 
concentrated product is another challenge in manufacturing. Process or product-related 
impurities lead to instable molecules which carry high risk of degradation during or after 
manufacturing, when the product is being stored or shipped, and put the safety of the drug in 
a considerable threat (Schneider, 2008; TreDenick, 2018). 
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2.7.3. High Costs as a Consequence and Challenge to Patient Access 
Eventually, all of the difficulties in the research, development, and manufacturing 
stages are eventually reflected in the expenses, which therefore affects the price of the 
product. Supporting that, monoclonal antibody therapeutics are considered amongst the most 
expensive drugs. To produce these biologics, mammalian cells are needed in vast number of 
cultures, as well as massive purification steps under Good Manufacturing Practice (GMP) 
circumstances are required, which results in exceptionally high manufacturing costs 
($300/gram). To give an example, the cost of FDA-approved Raxibacumab, recombinant 
human antibody developed by Human Genome Sciences (HGS), was $5,100 per each dose 
when stockpiled (Gang Hu and Nagata, 2016). Likewise, the yearly supply of alemtuzumab 
to be used in the treatment of leukaemia costed approximately $61,000 in 2014 (Liu, 2014). 
As a consequence, the accessibility of monoclonal antibody therapeutics to every patient in 
need is another concern. 
2.7.4. Side Effects and Safety Concerns 
Even though monoclonal antibodies have been exposed to great interest by the 
pharmaceutical industry by means of their therapeutic applications and future potential, the 
adverse reactions are still present and unavoidable with the current technology (Santos et al., 
2018). The adverse reactions become much crucial if the monoclonal antibody type is not 
similar to human immune system (Santos et al., 2018). 
2.8. The Potential of Monoclonal Antibodies for the treatment of COVID-19 
Pandemic 
COVID-19, caused by an infection with severe acute respiratory syndrome 
coronavirus 2 (SARS-Cov2), occurred in Wuhan, China in December 2019 and was declared 
as “pandemic” by The World Health Organization (WHO) in March 2020 (WHO, 2020). It 
hit over 24 million people worldwide resulting in over 833,000 death by August 27, 2020.  
There are multiple ongoing studies about the disease worldwide in which monoclonal 
antibodies show hope for the treatment of the global pandemic. The USA, The UK, China, 
South Korea, Germany, France, Italy, Switzerland, Singapore, Belgium are some of the 
countries in which several studies are being conducted about monoclonal antibody 
therapeutics to be used in the treatment of COVID-19 (CAS, 2020). 
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Not surprisingly, many institutions and universities have taken an immediate action 
to develop vaccine against the virus. However, developments in monoclonal antibody 
therapeutics are also as important as vaccine discovery (Ledford, 2020). This is especially 
because of the advantage that monoclonal antibodies require much shorter time to be 
developed compared to vaccines, which is a fascinating benefit when the incredibly spreading 
virus is considered in such pandemic, and also for being hope to patients who have already 
been infected. Furthermore, monoclonal antibody therapeutics are already a designer 
versions of the antibodies that would be produced by the immune system against SARS-
CoV-2 with the presence of the vaccine in the circulation, therefore, they promise even a 
shorter distribution within the circulation as another advantage (Ledford, 2020). 
According to Luo, (Luo et al., 2020), exceedingly proinflammatory cytokines have 
been detected in high concentration in patients who died because of COVID-19. In addition 
to that, cytokine storms which trigger multiple organ dysfunction, cardiovascular failure, and 
immediate death, have been spotted in a great population of patients in critical condition due 
to overproduction of proinflammatory cytokines. Thus, treatment of cytokine storms together 
with their early detection and prevention play an important role for COVID-19 patients (Luo 
et al., 2020).  
 Interleukin 6 (IL-6) is one of the cytokines involved in those cytokine storms 
stimulated by COVID-19. Therefore, tocilizumab, a humanized monoclonal antibody, is 
recommended as an anti-interleukin-6 receptor (anti IL-6R) for patients in critical conditions, 
prohibiting the accumulation of IL-6 (Luo et al., 2020). Supporting this research, another 
study is being carried out in the University College Dublin (UCD) School of Medicine, and 
shows that patients with critical conditions avoid the need for mechanical ventilation with 
tocilizumab use, which is originally used in the treatment of inflammatory arthritis. 193 
patients diagnosed with COVID-19 disease were assessed for the use of tocilizumab. 8 of 
them were deemed severe, and 6 of them were treated with tocilizumab at a maximum dose 
of 800 mg per injection with a repeated dose in every 12 hours. An immediate progress was 
observed in these six patients after the treatment, as they did not need ventilation support and 
discharged from the hospital in a week (McCarthy et al., 2020; Gorey, 2020; Guaraldi et al., 
2020). According to the studies, treatment with tocilizumab is in correlation with a lowered 
22 
 
death or need of invasive mechanical ventilation. Tocilizumab is currently being tested in 
more than 55 clinical studies for COVID-19 patients (Kaplon et al., 2020).  
Another anti-rheumatoid “monoclonal antibody” drug levilimab, is being 
investigated as a possible treatment of COVID-19 that targets IL-6 receptor. By June 5, 2020 
it obtained a state authorization in Russia only, through an accelerated procedure in 
accordance with the Decree No. 441 of the Government of the Russian Federation, effective 
as of April 4, 2020 as a result of a multicentre, randomized, double-blind and placebo-
operated Phase III clinical trial (NCT04397562). This clinical trial was conducted with 204 
participants who were administered a single dose mg 324 mg levilimab subcutaneously, 
combined with standard therapy and the results showed reduced lethality among the patients 
suffering with COVID-19 (Biocad, 2020; TAS, 2020). 10 out of 45 patients, including a 92-
year-old-man, were discharged in the first 14 days of trials while the health condition of the 
remaining 35 patients endured satisfactory (CGTN, 2020). 
Itolizumab, a humanized monoclonal antibody, is another urgently authorized 
medicine developed by Biocon and formerly approved in India for the treatment of plaque 
psoriasis. Emapalumab, canakinumab, ravulizumab are among other monoclonal antibody 
therapeutics that have already been marketed and currently under investigation for COVID-
19 (Kaplon et al., 2020). 
2.9.  Conceptual Framework 
In accordance with the findings from the literature review, the promising aspects of 





Fig. 2.10. The conceptual framework of the promising aspects of the monoclonal 
antibodies. 
 
According to the findings from the literature review, the challenges in the 
development and therapeutic use of monoclonal antibodies are summarized as a conceptual 
framework in Figure 2.11. 
Both of the conceptual frameworks will shape the research strategy is this study and 
form the pillars of the primary research. The research strategy is discussed in detail in the 





Fig. 2.11. The conceptual framework of the challenges in the development and therapeutic use 




CHAPTER III: RESEARCH METHODOLOGY AND METHODS 
3.1. Research Philosophy 
Research philosophy is a term used to describe the form of beliefs and assumptions 
in the knowledge improvement process of research, where assumptions are an integral part 
of the research as they form all aspects of projects and reflect the point of view of the 
researcher. There are three fundamental research philosophies (Saunders et al., 2019): 
• Ontological assumptions are about the nature of the truth, which influence what 
research objects and phenomena to concentrate on, how to see and approach them. 
• Epistemological assumptions are based on the source of knowledge. 
• Axiological assumptions consider the part of values and ethics throughout the 
research development, which integrate questions about how researchers manage their 
own values along with those of research participants. 
 
 
Fig. 3.1. The connection between beliefs and assumptions, research philosophies, and 
research design (Saunders et al., 2019). 
Research philosophies also can be distinguished according to where their assumptions 
are assessed on the objectivism-subjectivism bands (Saunders et al., 2019): 
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• Objectivism contains assumptions of the natural sciences. It implies realist ontology, 
epistemology centred on the finding of truth through observable and measurable facts, 
and represents a value-free, independent axiology. 
• Subjectivism integrates assumptions of the arts and humanities. It implies nominalist 
ontology (which believes that social phenomena are shaped with the language, 
insights and resulting activities of social actors), epistemology centred on the 
thoughts, narratives, understandings, perceptions of social actors and represents a 
value-bound, reflexive axiology. 
The variations and similarities in the ontological, epistemological, and axiological 
assumptions can root for various other paradigms to occur. Some of them are positivism, 
critical realism, interpretivism, relativism, pragmatism, determinism, etc. (Saunders et al., 
2019). 
As part of this study titled “Monoclonal Antibodies as Promising Therapeutic Agents in 
the Pharmaceutical Industry”, the philosophy of positivism is more likely to be used in order 
to evaluate the progression of monoclonal antibody therapeutics over time since the 
discovery. The information to be used will be objective and based on scientific facts, thus, 
positivism was deemed more appropriate as this philosophy firmly centres on scientific 
empiricist methods intended to generate genuine information and facts regardless of the 
human influence (Saunders et al., 2019).  
However, there may not always be one truth about the identification of the challenges in 
the development and regulatory approval procedures of monoclonal antibodies. The 
challenges can be depending on the process, circumstances, different perceptions, or else. 
For this reason, and because of the fact that the determination of the difficulties would be the 
first step of problem-solving process, this part of the research will be conducted with a 
blended philosophy of relativism and pragmatism influences. 
Similar to that, there is no one true reality when it comes to assess the implementation of 
monoclonal antibodies into recently emerged diseases, as well as to evaluate the potential of 
monoclonal antibodies as novel therapeutic agents in the pharmaceutical industry. This is 
because the therapeutic use of monoclonal antibodies is a brand-new technology and the 
uncertainties are ongoing, which makes the subject open to criticism combined with scientific 
facts. To give an example, tocilizumab, a monoclonal antibody that is mentioned in the 
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Chapter II, have been commonly used for the treatment for inflammatory diseases. 
Nevertheless, the possible therapeutic approach of tocilizumab against COVID-19 is now 
currently being discussed and investigated with limited information, as the drug has never 
been used in the treatment of infectious diseases, which allows the researcher to consider the 
philosophy of critical realism. 
Likewise, analysis of the therapeutic use and challenges of monoclonal antibodies from 
different perspectives require interpretative information from different professionals in the 
associated disciplines even though it roots to a scientific concern. Thus, the philosophies 
relativism and critical realism will be included for this part as well. 
3.2. Research Approach 
According to Saunders, three fundamental approaches to generate theories for 
research are listed as: 
• Deduction, when theories and hypotheses are generated prior to the research, and 
research strategy is intended to assess the hypotheses. 
• Induction, when the information is gathered, and theories are developed as a 
consequence of the data evaluation. 
• Abduction (also referred as “retroduction”, especially by critical realists), when 
information is used to discover a fact, identify topics, and clarify relationships, 
in order to create a new theory or revise a current one which is consequently 
tested, frequently via extra data collection (Saunders et al., 2019). 
During this research, abduction approach will be taken into consideration for most 
of the time as there are many issues to uncover about the therapeutic use, production, 
challenges, and potential of monoclonal antibodies. 
On the other hand, induction approach is deemed more appropriate for the primary 
research which concerns the assessment of therapeutic use and challenges of monoclonal 
antibodies from different perspectives of professionals in the associated disciplines, as this 
part of research will have a conclusion on its own that allows the researcher to build theories. 





3.3. Methodological Choice 
The representation of methodological choices and research design types is provided 
in Figure 3.2. 
 
Fig. 3.2. Methodological choices and research design types (Saunders et al., 2019). 
Methodological choice of a research relies on whether the data to be collected will be 
quantitative, qualitative or a mixed of both. The methodological choice is followed by 
determining on the method: mono, multi, or mixed methods as part of a research design.  
• Quantitative research design is when the data collection relies on numbers, and 
results are generally presented as statistics, graphs, etc. 
• Qualitative research design is independent from numeric data, which utilizes more 
of images, expressions, video clips, audio recordings, or other sources as material. 
• Mixed research design consists of both quantitative and qualitative data. An 
example to this can be a questionnaire with both closed and open-ended questions 
(Saunders et al., 2019). 
In this research, both of quantitative and qualitative data will be generated, therefore, 
the research design will be mixed. Supporting that, according to Saunders, pragmatism and 
critical realism, which are the research philosophies of this study, are often associated with 
mixed method designs. The combination of quantitative and qualitative data can be either 
simple or complex: 




• Mixed methods study (complex) is used when quantitative and qualitative data are 
collected sequentially. 
As per the assessment of the progression of monoclonal antibody generation since the 
discovery, the current challenges in the development and therapeutic use of monoclonal 
antibody therapeutics, and their potential as novel therapeutic agents in the pharmaceutical 
industry, qualitative data will be used. 
In order to analyse the different perspectives about therapeutic use and challenges of 
monoclonal antibodies by professionals from the associated disciplines, quantitative data 
will be collected. As the intention is to collect data from different perspectives, the number 
of participants is a concern. Quantitative data at this stage may help researcher to find more 
professionals to contribute the research, as the question types used for quantitative data are 
less time-consuming to answer. Therefore, larger number of professionals may volunteer to 
contribute, resulting in increased data accuracy. 
3.4. Research Focus 
The focus of a research can be exploratory, descriptive, explanatory, evaluative or a 
blend of these (Saunders et al., 2019): 
• Exploratory research aims to gain understanding about a topic of interest and tries 
to comprehend what is going on. 
• Descriptive research intends to gain an exact profile of actions, individuals or 
conditions. 
• Explanatory research creates casual connections among variables.  
• Evaluative research aims to figure out how well something functions. 
• Combination of different types on the other hand, may be achieved by following 
multiple techniques as per research design. 
In this research, exploratory nature, combined with evaluative nature will be 
considered. Being one of the aspects of exploratory research, the route of this study may 
change according to new updates as COVID-19 pandemic is present and new insights may 
come up during the research. Exploratory research may also initiate with a wide focus which 
will eventually become narrower as the research develops (Saunders et al., 2019). Almost all 
of the objectives of this research reflect evaluative nature, and root to understand how 
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efficient monoclonal antibodies work, how fast did the monoclonal antibody technology 
evolve, to what extent they show promise for diseases that are lack of treatment, and how did 
the market profile and investment focus of the pharmaceutical companies altered. 
3.5. Research Strategy 
There are different strategies in order to conduct a research project. Possible strategies 
can be listed as: experiment, survey, documentary and/or archival research, case study, 
ethnography, action research, grounded theory, narrative inquiry. 
From the strategies above, this research will follow survey and archival research 
strategies. Many of the archival sources are currently available online, which allows 
researcher to find more information in a certain time and suitable to qualitative data 
collection. However, online sources are not always high of quality and reliable. To solve this 
problem, sources from academic websites will be considered to achieve the first and fourth 
research objectives: 
• Science Direct 
• National Centre for Biotechnology Information (NCBI) 
• National Institute for Cellular Biology (NICB) 
• National Institutes of Health (NIH) 
• Social Science Research Network (SSRN) 
• PubMed 
• Google Scholar 
• Griffith College Library – online sources, or organizational websites such as 
European Medicines Agency (EMA), Food and Drug Administration (FDA), and 
published academic books. 
Survey on the other hand, is seemingly the most appropriate option in order to collect 
quantitative data for the remaining research objectives. Survey strategy may consist of 
questionnaire, structured observation and/or interviews as a data collection technique where 
questions are standardised and asked of all participants (Saunders et al., 2019). To collect 
quantitative data from professionals regarding the therapeutic use and challenges about 
monoclonal antibodies, four questionnaires will be prepared to be presented to professionals 
in these fields: 
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• Scientists, who have a broad knowledge about the disease mechanism in which 
monoclonal antibodies are considered as possible drug candidates. They can 
evaluate the function of monoclonal antibody therapeutics specific to a disease. 
• Medical Doctors, who can evaluate the use of monoclonal antibody therapeutics 
by means of health risks to patients. They can express more about the risk/benefit 
balance of monoclonal antibodies by giving real life examples from their patients. 
• Regulatory Professionals, who can consider the monoclonal antibody use from a 
regulatory perspective. 
• Pharmaceutical/Biotechnology Professionals, who can state their opinion about 
monoclonal antibody therapeutics from a more production and development – 
related perspective. 
The consent form will be provided to all of the respondents before their participation 
to the questionnaire. A sample of the consent form can be found in Appendix C. Followed 
by, the first section (Section A) will also be common for each group of professionals to be 
asked name/surname, level of education, profession, area of specialty, and years of 
experience. Likewise, a sample of the Section A is provided in Appendix D. The respondents 
are presented in detail in Chapter IV, prior to analysis of the data. 
The questionnaire will most of the time contain quantitative questions, and complex 
questions will be avoided to convince more professionals to contribute. The online 
questionnaire will be shared on LinkedIn platform also mentioned in two different webinars 
in order to find more participants: 
• "Therapy of Relapsed-Refractory Multiple Myeloma: Challenges and Current 
Options", by Springer Healthcare, held on June 24th, 2020. 
• "Understanding Genomics and Genetic Testing in Cancer Immunotherapy", by 
Cancer Research Institute, held on June 24th, 2020. 
The Section B of the questionnaire will be specific for each group of professionals. 
However, some of the questions will remain same as long as the content is relevant. 
According to Chapter II, developing monoclonal antibody therapeutics are challenging 
overall. However, finding out the prominent factor which makes the process relatively more 
difficult than others, and focusing on its improvements would be the first step of the possible 
solutions. For this reason, as well as to achieve the second research objective, scientists and 
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pharmaceutical/biotechnology professionals will be asked six challenging factors in the 
development of monoclonal antibody therapeutics. The factors will include: 
• Challenges in drug design and formulation, 
• Challenges in chemical structure, 
• Undesirable by products generated during manufacturing and processing, 
• Uncertainties about the safety of monoclonal antibody therapeutics, 
• Insufficient knowledge about the effectiveness of monoclonal antibody 
therapeutics, 
• Challenges in biodistribution of the molecule. 
All of the respondents will be asked if they agree that monoclonal antibodies are 
overpriced, after that if there is any governmental funding/support for the use and 
development of monoclonal antibodies in their country, aiming to gain an awareness about 
the global support for monoclonal antibodies. 
Medical doctors, as the professionals who are the closest to patients, and therefore 
one of the most appropriate profession for the evaluation of the safety of the drugs, will be 
asked whether they agree monoclonal antibodies are safe to use for therapeutic approach. 
The effectiveness of monoclonal antibodies as a newly developed treatment for diseases, as 
well as the risk/benefit balance of monoclonal antibodies will be among the questions to be 
asked for scientists and medical doctors. 
Additionally, regulatory professionals will be asked whether they agree that the 
regulations in their countries are adequate enough to ensure patient safety, product quality 
and efficacy. Moreover, they will be asked if they agree that regulatory differences between 
countries have a significant influence on the development/clinical use of monoclonal 
antibodies as a challenge, aiming to provide a brief overview to global regulatory perspective 
for monoclonal antibody therapeutics. 
To achieve the third research objective, all of the respondents will be questioned 
about their agreement on future growth of therapeutic use of monoclonal antibodies. 
Moreover, there will be only one qualitative question for all respondents: "I would be very 
interested to hear from you if you would like to share any additional information, thoughts, 




Quantitative results will be presented in tables and charts. Qualitative results will be 
provided as description in the tables. As a result, statistics will be both inferential and 
descriptive. 
A sample of the Section B of the questionnaire for scientists can be found in Appendix 
E. Likewise, sample for medical doctors is provided in Appendix F, for regulatory 
professionals in Appendix G, and for pharmaceutical/biotechnology professionals in 
Appendix H. 
3.6.  Time Horizon 
The time period of a research can be divided into two groups: 
• Cross-sectional, when a research is completed at a certain time frame, and 
different population groups are observed. 
• Longitudinal, when a research is conducted over a given period, sometimes 
taking many years, and same topics are observed over time (Saunders et al., 
2019). 
This research will use cross-sectional time horizon, as there will be a time limitation 
and the topic will be assessed by different samples, such as assessment of regulatory, 
scientific, or medical perspective on monoclonal antibody therapeutics, or their development 
and challenges. 
 
Fig. 3.3. Research onion (Saunders et al., 2019), and the followed techniques for this study. 
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3.7.  Ethical Concern 
Research ethics form a significant part of building the research design. This research 
will be conducted in accordance with the principles below: 
• The researcher will avoid any activity that cause data inaccuracy such as fraud, 
dishonesty, deception, partiality, misrepresentation, etc. To give an example, all the 
questionnaires will be filled by real professionals in the required field, and their 
responses will not be altered. Likewise, the outcome of the research will not be 
falsified. 
• The researcher will respect to the rights of the participants. Professionals will be 
informed that participation to the questionnaire is voluntary and they may withdraw 
at any time. 
• The researcher will respect to the confidentiality of the participants. Their personal 
information will not be shared with public and the responses will be used for scholarly 
purposes only. As the questionnaire will be shared with public through LinkedIn, 
name/surname will be asked in order to prevent random participation of people with 
unmatched qualifications causing data inaccuracy. In case the researcher contacts 
directly with the possible participant, they will be offered a choice to participate 
anonymously as A.O. for instance, instead of Alara Ozen. 
• Any activity that may cause embarrassment, pressure, discomfort, mental or physical 
harm, stress, pain or else to participants will be avoided (Saunders et al., 2019). 
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CHAPTER IV:  DATA ANALYSIS 
This chapter will present the data and results obtained from the primary and secondary 
research, according to the research objectives. 
4.1. Demographic Representations of the Respondents 
4.1.1. The Various Professions of Respondents 
The distribution of the participants according to their professions are shown in Table 
4.1., and Figure 4.1. 
Table 4.1. The representation of the number of the participants according to their 
professions. 
Profession Frequency % Frequency 
Scientists 45 45.91% 
Medical Doctors 21 21.42% 























The study was carried out with 45 scientists (45.91%), 21 medical doctors (21.42%), 
7 regulatory professionals (7.14%), pharmaceutical/biotechnology professionals (25.51%), 
which accounts for 98 respondents in total. 
4.1.2. The Highest Level of Education of the Respondents 
The distribution of the participants according to their highest level of education are 
shown in Table 4.2., and Figure 4.2. 
Table 4.2. The distribution of the highest level of education attained by the respondents 
according to their professions. 





















































Fig. 4.2. The representation of the highest level of education attained by the respondents 





0 5 10 15 20 25 30 35 40
Bachelor of Science (BSc)
Master of Science (MSc)
Doctor of Medicine (MD)
Doctor of Philosophy (PhD)
37 
 
Among the 98 respondents in total, 36 (36.73%) of them held PhD degree as the 
highest qualification, followed by 17 (17.34%) MD degree holders, 36 (36.73%) MSc degree 
attainders’, and 9 (9.18%) participants with BSc degree. 
The 36 respondents awarded with PhD degree consisted of 23 scientists, 4 medical 
doctors, a regulatory professional, and 8 pharmaceutical/biotechnology professionals. All of 
the 17 MD degree holders were medical doctors. Another group of 36 respondents with MSc 
holders included 20 scientists, 5 regulatory professionals, 11 pharmaceutical/biotechnology 
professionals. BSc holders with a number of 9 participants, comprised of 2 scientists, a 
regulatory professional and 6 pharmaceutical/biotechnology professionals. 
4.1.3. The Experience with Monoclonal Antibody Therapeutics of the Respondents 
The participants were asked if they have had any working experience with 
monoclonal antibody therapeutics, which could be in the research and development, 
regulatory procedure, or manufacturing department, as well as treating patients with 
monoclonal antibodies, depending on the profession of the respondents. The results are given 
in Table 4.3., and Figure 4.3. 
Table 4.3. The respondents according to their experience of working with monoclonal 
antibodies. 
 Yes No 
Scientists 31 (31.63%) 14 (14.28%) 
Medical Doctors 11 (11.22%) 10 (1.02%) 
Regulatory Professionals 7 (7.14%) - 
Pharmaceutical/biotechnology 
professionals 
21 (21.42%) 4 (4.08%) 






Fig. 4.3. The demonstration of the respondents according to their experience of working 
with monoclonal antibodies. 
31 (31.63%) scientists, 11 (11.22%) medical doctors, 7 (7.14%) regulatory 
professionals, 21 (21.42%) pharmaceutical/biotechnology professionals, that accounts for 70 
participants overall (71.4%), have stated that they have had working experience with 
monoclonal antibodies. On the other hand, 28 participants (28.57%) consisting of 11 
scientists, 10 medical doctors, 4 professionals from the pharmaceutical/biotechnology 
industry have stated that they have not had any experience of working with monoclonal 
antibodies.  
4.2. Analysis of the Objective 1: Assessment of the progression of monoclonal antibody 
generation over time to provide better quality, safety and efficiency of the product and 
advance its therapeutic use. 
The pharmaceutical industry has made a great progress by means of their approach to 
develop monoclonal antibody types with reduced immunotoxicity. Development of human-
like or human-sourced monoclonal antibodies plays a key role in this issue. In order to assess 
the progression that the pharmaceutical industry has made so far, the antibody formats of 
approved monoclonal antibody therapeutics within the 10 years is given in Table 4.4., and 
Figure 4.4, with a separate presentation of [2010-2014] and [2015-2019] for a better 
comparison. The sources of the list of approved drugs by years and their antibody formats 










Table 4.4. The distribution of globally marketed monoclonal antibody therapeutics according 
to their antibody format. 




































Fig 4.4. The representation of globally marketed monoclonal antibody therapeutics between 
2010-2014 and 2015-2019 according to their antibody format (Strohl, 2014; Lu et al., 
2020). 
According to Table 4.4., and Figure 4.4., the number of approved monoclonal 
antibody therapeutics between [2010-2019] was 80. Throughout the 10-year period of time, 
only 16 (20%) therapeutics year was approved in the first half period, which included 1 
mouse/murine, 2 chimeric, 7 humanized, 6 human sourced monoclonal antibodies. The 
second 5-year period comprises 64 (80%) therapeutics which included a mouse/murine, 2 
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4.3. Analysis of the Objective 2: Identification of the current challenges in the 
development and therapeutic use of monoclonal antibody therapeutics. 
The current difficulties in the development of monoclonal antibody therapeutics have 
previously been mentioned within the Chapter II. In parallel to those findings, respondents 
were asked various questions about the challenges depending on their profession. 
4.3.Q1: Do you agree that there are certain factors can influence the development process 
of monoclonal antibodies? 
The scientists and professionals from the pharmaceutical/biotechnology industry 
were asked six possible factors that can impact on the development process of monoclonal 
antibodies as their profession were deemed the most relevant for this question. 45 scientists 
and 25 pharmaceutical/biotechnology industry professionals that accounts for 70 respondents 
in total were questioned. The results are shown in Table 4.4, also represented in Figure 4.4 
as bar charts. 
Table 4.5. The point of view of the scientists and pharmaceutical/biotechnology 











































































































Fig. 4.5. The demonstration of the viewpoints of the scientists and 
pharmaceutical/biotechnology professionals for the factors that can influence the 
development of monoclonal antibodies. 
Of the 70 respondents that consisted of scientists and pharmaceutical/biotechnology 
professionals, 57 (81.42%) agreed with the statement that drug design and formulation is a 
challenging factor that can influence the quality and the development of the monoclonal 
antibody therapeutics, of which 29 among them even strongly agreed. 10 respondents 
(14.28%) felt neutral with the statement, while 3 (4.28%) disagreed. 
Chemical structure of monoclonal antibodies was given as another challenge that can 
influence the development of monoclonal antibodies. According to the results, 49 
respondents (70%) believed that chemical structure is a factor that requires critical 
consideration in the development process, of which 22 among them even strongly believed. 
14 (20%) felt neutral, while 7 (10%) disagreed. 
A vast majority of the respondents, 50 (71.42%) agreed with the statement that 
undesirable by products generated during manufacture and processing can have a crucial 
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17 among the supporters of this statement even strongly agreed. 14 (20%) felt neutral. 6 
(8.57%) participants on the other hand, disagreed. 
47 (67.14%) of the 70 respondents agreed with the statement that the current knowledge 
about monoclonal antibody therapeutics is not adequate to ensure their safety, of which 17 
among them even strongly agreed. 12 (17.14%) respondents remained neutral, while 11 
(15.71%) disagreed. 
Likewise, another group of 38 (54.28%) respondents were in favour of the statement 
that the existing information is not sufficient to state that monoclonal antibody therapeutics 
are effective. 14 (20%) professionals felt neutral. 27 (38.57%) of the respondents were in 
disagreement with the statement, of which 14 of them even strongly disagreed. 
Biodistribution of monoclonal antibody therapeutics was given as the final factor in 
which large number of respondents, 53 (75.71%), considered it as a challenge for the 
development of monoclonal antibodies while 13 (18.57%) professionals felt neutral, 4 
(5.71%) disagreed. 
Overall, with a significant percentage of 81.42% among scientists and 
pharmaceutical/biopharmaceutical professionals, drug design and formulation is considered 
as the most challenging factor that impacts on the development of monoclonal antibodies, 
followed by biodistribution of the molecule (75.71%), undesirable by products generated 
during manufacture and processing (71.42%), and chemical structure (70%). Uncertainties 
about the safety of the product (67.14%) and insufficient knowledge about the effectiveness 
of monoclonal antibody therapeutics (54.28%) were considered less problematic compared 
to other factors but yet the percentage of the supporters of these factors is above average. 
4.3.Q2. Do you agree or disagree with the statement that monoclonal antibodies are 
overpriced? 
The high costs of monoclonal antibody therapeutics as a challenge to patients’ access 
have previously been discussed in the Chapter II. Relating to that, all of the respondents were 
asked about the economic situation of monoclonal antibody therapeutics. The results are 





Table 4.6. The points of views of the total respondents to the question whether they find 






















Fig. 4.6. The demonstration of the points of views of the total respondents to the question 
whether they find monoclonal antibodies overpriced. 
59 (60.20%) of the 98 participants, representing the majority, agreed with the 
statement that monoclonal antibodies are overpriced. 27 of the respondents (27.55%) felt 
neutral, while 12 (12.24%) disagreed. Two respondents of the 27 who opted for neutral, 
stated that they believe monoclonal antibodies are equally expensive to produce. 
4.3.Q3: Is there any governmental funding/support in your country for the use or 
development of biologics/monoclonal antibodies? 
As a consequence of the various challenging factors in the generation of monoclonal 
antibodies; research and development process as well as manufacturing can consist of many 
repeated actions to attain a high quality, safe and effective product in the end. Likewise, the 














was identified as another difficulty. At this point, governmental funding/support can have a 
significant impact on the improvements for monoclonal antibody development. For this 
reason, respondents were asked if they have any governmental funding/support in their 
country for the use or development of monoclonal antibodies. The aim for asking this 
question was to gain awareness about the global support for monoclonal antibodies. The 
results obtained are shown in Table 4.7., and Figure 4.7. 
Table 4.7. The outcomes from the respondents questioned whether any governmental 
funding/support exists in their country for the use or development of biologics/monoclonal 
antibodies. 
 












Fig. 4.7. The representation of the outcomes from the respondents questioned whether any 
governmental funding/support exists in their country for the use or development of 
biologics/monoclonal antibodies. 
51 respondents out of 98 (52.04%) stated that they have governmental support for 
the use or development of biologics/monoclonal antibodies, while 31 (31.63%) answered 
negatively, and 16 (16.32%) were unsure if any support existed in their country. 
32 of the respondents (32.65%) provided the type of the governmental support and 










Table 4.8. The countries and the type of the governmental funding/support for the use and 




• Food and Drug Administration (FDA), 
• National Institutes of Health (NIH), 
• Biomedical Advanced Research and Development Authority 
(BARDA), 
• “Medicare and Medicaid exist in the USA, which governs the kind 
of treatment for particular age groups and categories of patients. It 
mainly covers prescription medicine, but since a few years back, we 
now have the addition of biologics to the list of treatments 
undertaken by these schemes” 
India 
• Biotechnology Industry Research Assistance Council (BIRAC) 
• Central Drugs Standard Control Organisation (CDSCO) 
• Indian Council of Medical Research (ICMR) 
• The Department of Science and Technology (DST) 
• Department of Biotechnology (DBT) 
Ireland 
• Industrial Development Authority (IDA) 
• Science Foundation Ireland (SFI) 
• Enterprise Ireland 
• “Depending on the indication, some types of monoclonal 
antibodies are reimbursed in Ireland.” 
Turkey 
• The Scientific and Technological Research Council of Turkey 
(TUBITAK) 
• Health Institutes of Turkey (TUSEB) 
• Turkish Social Security Agency (SGK) 
Norway 
• The Research Council of Norway 
• Innovation Norway 
• Life Science Cluster 
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Germany • German Research Foundation (DFG) 
The UK • Cancer Research UK (CRUK) 
 
Table 4.8 shows that 32.65% of the respondents were aware of the governmental 
support/funding in the specified countries. 
4.3.Q4: Do you agree or disagree with the statement that monoclonal antibody therapeutics 
are safe to use? 
In order to analyse the safety concern for the therapeutic use of monoclonal antibodies 
from real-life examples, the viewpoints of medical doctors were asked independently from 
other professionals. The results are presented in Table 4.9., and Figure 4.8. 
Table 4.9. The perspective of medical doctors whether they agree that monoclonal 





















Fig. 4.8. The representation of the perspective of medical doctors whether they agree that 














A vast majority of medical doctors, 18 (85.71%) out of 21, were in favour with the 
statement that therapeutic use of monoclonal antibodies is safe. 3 (14.28%) doctors remained 
neutral, while none of them disagreed. 
4.3.Q5: Do you agree or disagree with the statement that monoclonal antibodies are 
effective as a newly developed treatment for diseases? 
The effectiveness of the monoclonal antibodies for the most frequent application area 
of them was asked to both scientists and medical doctors, as a scientist is more skilled in 
evaluating the disease-drug mechanism in a molecular scale, while a doctor can consider real 
life examples through their patients. This question was answered by 45 scientists and 21 
medical doctors, which accounts for 66 people in total. The findings are shown in Table 4.10 
and Figure 4.9. 
Table 4.10. The perception of scientists and medical doctors whether they find monoclonal 
















































Fig. 4.9. The representation of the perception of scientists and medical doctors whether 
they find monoclonal antibodies effective as a newly developed treatment for diseases. 
31 scientists and 18 medical doctors, which accounts for 49 (74.24%) of the 66 
respondents supported the statement that monoclonal antibodies are effective as a newly 
developed treatment for diseases, while 16 (24.24%) remained neutral, and 1 (1.51%) 
disagreed. 
When the statistics are evaluated individually according to the professions, 31 
(68.88%) of the 45 scientists and 18 (85.71%) of the 21 medical doctors agreed. 14 (31.11%) 
out of 45 scientists and 2 (9.52%) out of 21 medical doctors felt neutral. 
4.3.Q6: Do you agree or disagree with the statement that the benefits of monoclonal 
antibodies outweigh the risks?  
A group of 66 respondents, which includes 45 scientists and 21 medical doctors were 
questioned if they agree with the statement that benefits of monoclonal antibodies outweigh 






















Table 4.11. The responses of scientists and medical doctors whether they agree to the 
statement that benefits of monoclonal antibodies outweight the risks. 
















Fig. 4.10. The representation of the perception of scientists and medical doctors on the 
benefit/risk balance of monoclonal antibodies. 
45 (68.18%) respondents out of 66 agreed with the statement that monoclonal 
antibodies are beneficial and worth to use even though they carry risks. 19 (28.78%) 
respondents felt neutral, 2 (3.03%) respondents disagreed. 
The questions 4.3.Q7 and 4.3.Q8 were as part of the opportunity to ask regulatory 
professionals individually who work in consultancy companies for biotechnology industry, 
from countries including the USA, Ireland, India. The purpose was to provide a brief 















4.3.Q7: Do you agree or disagree with the statement that the regulations for 
biologics/monoclonal antibodies in your country are adequate enough to ensure product 
efficacy, quality, and patient safety? 
Table 4.12. The point of views of the regulatory professionals on their agreement or 
disagreement that the regulations for biologics/monoclonal antibodies in their country are 




















Fig. 4.11. The representation of the point of views of the regulatory professionals on their 
agreement or disagreement that the regulations for biologics/monoclonal antibodies in their 
country are adequate enough to ensure product efficacy, quality, and patient safety. 
5 (71.42%) of the 7 regulatory professionals supported the statement that the 
regulations for biologics/monoclonal antibodies in the USA, India, and Ireland are adequate 
enough to ensure product efficacy, quality, and patient safety. 2 (28.57%) of the regulatory 
professionals from India remained neutral, while none of the respondents disagreed. 
2 (India)












4.3.Q8: Do you agree or disagree with the statement that regulatory differences between 
countries have a significant impact on the development/clinical use of monoclonal 
antibodies? 
Table 4.11 and Figure 4.12 presents the point of views of the regulatory professionals 
whether they agree to the statement that regulatory differences between countries have an 
important influence on the development/clinical use of monoclonal antibodies. 
Table 4.13. The perceptions of the regulatory professionals on their agreement or 
disagreement that regulatory differences between countries have a significant impact on the 




















Fig. 4.12. The representation of the perceptions of the regulatory professionals on their 
agreement or disagreement that regulatory differences between countries have a significant 
impact on the development/clinical use of monoclonal antibodies. 
5 among the 7 regulatory professionals (71.42%) were in favour of the statement that 
regulatory differences between countries significantly affect the development/clinical use of 














4.4. Analysis of the Objective 3: Analysis of the therapeutic use and challenges of 
monoclonal antibodies from different perspectives of professionals.  
4.4.Q1: Do you agree or disagree with the statement that the use of monoclonal antibodies 
will grow in the future? 
All of the respondents were asked whether they believe the use of monoclonal 
antibodies will grow in the future. The results are shown in Table 4.14 and Figure 4.13. 
Table 4.14. The perceptions of respondents on their agreement or disagreement that the use 
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Fig. 4.13. The representation of the perceptives of the respondents on their agreement or 















An important number of 91 (92.85%) respondents out of 98, believed that the use of 
monoclonal antibody will grow in the future, of which 51 of them even strongly agreed. 6 
(6.12%) of the respondents remained impartial. One (1.02%) respondent disagreed. 
 
4.4.Q2: I would be very interested to hear from you if you would like to share any additional 
information, thoughts, or experience of working with monoclonal antibodies. 
This question was left optional to answer for participants and aimed to allow 
volunteer professionals share their experiences, knowledge, and point of views, also, to 
provide them the opportunity to freely explain their knowledge/point of view according their 
work experience with monoclonal antibodies. Table 4.15., and Fig. 4.14. show the number 
of positive perceptions and concerns/challenges about monoclonal antibodies stated by the 
participated professionals including scientists, medical doctors, regulatory professionals, 
pharmaceutical/biotechnology professionals. 
Table 4.15. The distribution of the positive perceptions and concerns/challenges about 














































Fig. 4.14. The distribution of the positive perceptions and concerns/challenges about 
monoclonal antibodies according to the professions of the respondents. 
Among the 98 respondents, 27 (27.55%) of them preferred to share additional 
information, thoughts, or experience of working with monoclonal antibodies. There were 18 
(66.66%) positive perceptions and 9 (33.33%) concerns/challenges received among 27 
shared knowledge/point of views.  
18 responses received from a group of 5 scientists, 4 medical doctors, one regulatory 
professional and 8 professionals from the pharmaceutical/biotechnology industry. On the 
other hand, 4 scientists, 2 regulatory professionals and 3 pharmaceutical/biotechnology 
professionals belonged to the group of 9 respondents who shared their concerns about 
monoclonal antibodies. The positive perceptions and concerns/challenges about monoclonal 















Table 4.16. The positive perceptions and concerns/challenges about monoclonal antibodies 
according to scientists. 
Monoclonal Antibody Therapeutics from the Perception of Scientists 
Positive Perceptions (55.55%) Concerns/Challenges (44.44%) 
“Monoclonal antibodies have a positive impact. 
Thus, monoclonal antibodies can be potentially 
effective to treat the rare disease in the near 
future.” 
“The first clinical trial (that I am aware of) 
involving mAbs resulted in almost all of the 
participants dying within days. That makes 
an impression- mAbs are incredibly powerful 
but difficult to predict. They’re relatively 
easy to make to produce but risky to actually 
use.” 
“I find the use of biologics and MoAbs to be 
increasingly necessary in furthering our 
expertise on how to treat/remedy various 
ailments, and I feel that their importance in the 
scientific field will only increase further in the 
future.” 
“The biosimilar market of biologics is still 
limited because these molecules are complex 
to produce and difficult to perfectly copy.” 
“Armed antibodies in B-cell lymphoma and T-
DM1 in breast cancer are really promising.” 
“The system for production is limited and 
needs to be improved. Cell viability is also 
big concern.” 
“I think mAb-based strategies for infectious 
disease control will grow as a result of COVID-
19 pandemic.” 
“I have seen some off-target effects in 
monoclonal antibody therapies in treating 
cancer which sometimes enhances mortality 
in patients. More research is definitely 
needed to explore the field and reduce the 
off-target effects.” 
“They are beneficial also quite expensive.”  
The positive perceptions in Table 4.16. show that scientists believe monoclonal 
antibodies are promising for future due to their positive impact on current diseases with no 
cure, their potential to success in the treatment of rare diseases, as well as their applications 
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in infectious diseases due to the urgent research focus on COVID-19 pandemic. One of the 
scientists mentioned high costs as a concern along with his positive response. 
As per concerns/challenges, scientists stated that the production system and 
biosimilar market of monoclonal antibodies are limited due to their complexity, and in certain 
conditions they can be unpredictable which ends up with mortality. 
The positive perceptions and concerns/challenges about monoclonal antibodies 
according to medical doctors is provided in Table 4.17. 
Table 4.17. The positive perceptions about monoclonal antibodies according to medical 
doctors. 
Monoclonal Antibody Therapeutics from the Perception of Medical Doctors 
Positive Perceptions (100%) 
“Monoclonal Antibodies are very highly emerging and are the future of healthcare. They are 
the answer to all the diseases that have been deemed impossible to cure up until now. My 
experience has allowed me to administer monoclonal antibodies and alleviate disease states 
mainly to do with organ transplantation, particularly of kidneys in patients. I have noticed that 
they reduced the risk of organ rejection by a relatively high degree. In my experience, they are 
a boon to me as a healthcare professional and to the patients that I have treated.” 
“They are the future of the medicine if improved.” 
“They are the medicines of the future. I think they will be precious especially for the treatment 
of cancer and autoimmune diseases.” 
“Excellent molecules but patient access is a concern because of high costs, need biosimilars.” 
Table 4.17 shows medical doctors agree that monoclonal antibodies can be solution 
for the currently untreatable diseases, and they encourage the use of monoclonal antibodies. 
They also believe they will construct the future of the pharmaceutical industry. Even though 
there is not any concern/challenge stated, one of the medical doctors mentioned patient access 
as a concern along with her positive response. 
The positive perceptions and concerns/challenges about monoclonal antibodies 
according to regulatory professionals is provided in Table 4.18. 
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Table 4.18. The positive perceptions and concerns/challenges about monoclonal antibodies 
according to regulatory professionals. 
Monoclonal Antibody Therapeutics from the Perception of Regulatory Professionals 
Positive Perceptions (50%) Concerns/Challenges (50%) 
“Regulatory bodies such as US FDA and 
EMA have well defined regulatory structure 
for mAbs approval and the approach is same 
as that of any biotechnological product.” 
“Potential safety studies in non-clinical trials 
are quite limited (only specific species are 
used) which makes it difficult to evaluate risks 
for human trials. Overall, more funding is 
needed for non-clinical development for 
better results in clinical trials and 
homogeneity of regulatory framework 
regarding mAbs are required globally not 
only in FDA or EMA.” 
“Biologics and biosimilar development and to 
get it approved is really challenging yet 
promising.” 
“ANDA submissions are filed based on the 
clinical data produced from the randomised, 
double blinded studies conducted. The 
challenge mainly included lack of volunteer 
and patient compliance in the trial.” 
According to Table 4.18, distinct regulatory structures by FDA and EMA for 
marketing approval of biologics/monoclonal antibodies, as well as the promising future of 
biological products were among positive perceptions. However, one respondent stated that 
that these regulatory procedures would be a bottleneck if they are not standardized globally. 
The limitations within pre-clinical and clinical studies were mentioned as other concerns due 
to lacking in subjects/volunteers and patient compliance. 
The positive perceptions and concerns/challenges about monoclonal antibodies 




Table 4.19. The positive perceptions and concerns/challenges about monoclonal antibodies 
according to pharmaceutical/biotechnology professionals. 
Monoclonal Antibody Therapeutics from the Perception of Pharmaceutical/Biotechnology 
Professionals 
Positive Perceptions (72.72%) Concerns/Challenges (27.27%) 
“I believe the use of solid-phase synthesis for 
mass-production of Fabs and Fab-drug-
conjugates will massively reduce price, giving 
industry a competitive advantage to scale-up 
production - business model will shift to high-
volume production, at much more affordable 
prices for patients and insurers. Expect this 
change in the next 5 years. Added bonus - less 
risk from bio-contamination since this is 
essentially chemical synthesis.” 
“Large corporations are far too risk-averse 
in this space. Industry needs to innovate in 
the basic manufacturing technology, to 
reduce costs, pass benefits on to patients, 
and consequently gain market share and 
boost profits in the long-term. Single-use 
bioreactors are already helping here, 
enabling rapid re-purposing, and 
simplifying validation and cleaning. Similar 
big-picture thinking is needed”. 
“The development of new Automated 
Technologies for Formulation, and especially for 
long-term Stability Testing would massively 
improve/simplify this aspect of antibody 
development, which is currently very tedious and 
labour-intensive (even if only one to two 
technicians work on this per product, it can be 
all-consuming and involve late-nights/weekends, 
every day, spanning months to years - which is 
draining and demotivating. Clear opportunity for 
innovation to improve working conditions.)” 
“Need new regulatory and technical 
guidance to avoid/screen for cytokine 
storms. (e.g. IL-6 driven over-
inflammation). (Ref: TGN1412 disaster).” 
“The antibody discovery industry is dynamic and 
exciting. There seems to be abundant growth for 
market opportunity and the advanced technology 
is incredibly innovative!” 
“Stability is a concern, need improvement 




“It is very useful in treatment of various diseases 
and are obtained from the mice plasma that can 
be later biotechnologically developed for its 
therapeutic purpose.” 
 
“As biopharmaceutical companies are coming 
up with biosimilar alternatives, the final cost will 
eventually be reduced in future.” 
 
“MAbs will be the future treatment 
predominantly.” 
 
“Use of Phage Display (directed evolution) is 
already revolutionising the basic discovery of 
these medicines.” 
 
“I am expecting that it will continue to grow and 
reach its peak point in the near future. Then, a 
more feasible therapeutic/therapeutic generation 
technique (such as CAR-Ts and m-RNA based 




In addition to the statistics received within the Table 4.6 about the high pricing of 
monoclonal antibody therapeutics from the Question 4.3.Q2., high costs of monoclonal 
antibodies are emphasized once again by scientists and medical doctors within the Table 
4.16, and Table 4.17. However, there is a positive perception from one of the 
pharmaceutical/biotechnology professional in the Table 4.19, recommending that if 
monoclonal antibodies could be produced on a larger scale with advanced manufacturing 
technologies, hopefully in the upcoming 5 years, it would be a hope for monoclonal antibody 
therapeutics to reduce the price. Additionally, the respondent stated that advancements in the 
future technologies may reduce the biocontamination risk as well. Another professional also 
specified the approach of developing biosimilar alternatives of monoclonal antibody 
therapeutics could be another opportunity for cost reduction. 
One of the respondents also referred to TGN1412 disaster as part of his concern about 
limited technical guidance from regulatory agencies, contrary to a positive perception stated 
by a regulatory professional in the Table 4.18. 
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4.5. Analysis of the Objective 4: Evaluation of the potential of monoclonal antibodies 
for the treatment of recently emerged COVID-19 pandemic. 
According to the optimistic clinical trial outcomes provided within the Chapter II, 
monoclonal antibodies show hope for the patients who suffer with COVID-19. The lowered 
need of intensive care unit, ventilation support, reduced death rate among infected patients 
in several clinical trials supports the view. Another benefit is that they are currently being 
investigated in all over the world with an extensive focus, which would inevitably improve 
the findings in much shorter time. Furthermore, their biochemical characteristics that would 
shorten the defence time against virus, as well as the advantage to be generated in a much 
shorter time than vaccines are added as extra benefits, as time is very critical in this case, in 
order to prevent the spread of the virus among nations. 
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CHAPTER V: DISCUSSION OF THE DATA ANALYSIS 
This chapter will discuss the key findings from the data analysis with regard to the 
fulfilment of research objectives of the study. 
The first objective of this study intended to evaluate the progression of the antibody 
generation techniques over time for better quality, efficacy, and safety of medicines thus to 
advance their therapeutic use. According to Figure 2.5., the pharmaceutical industry has seen 
a massive growth in the market value with the discovery of monoclonal antibodies and 
advancements in the generation of human-similar and human monoclonal antibody types. 
The growth of monoclonal antibodies has progressed in fast pace because of huge research 
and development investments due to their promising profile, especially for untreated severe 
diseases. The statistics of the approved monoclonal antibody formats in the first and the 
second half of the last 10 years show an impressive difference in a positive way, and ensures 
that it will continue to grow even much faster, especially with the developments in the genetic 
engineering methods such as transgenic mice technology (Figure 2.7.) and bispecific 
monoclonal antibodies (Figure 2.8.) which provide more efficient production and use of 
monoclonal antibodies. 
The purpose of the second objective was to identify the current challenges in the 
development of monoclonal antibody therapeutics. According to Table 4.5., scientists and 
pharmaceutical/biotechnology professionals 81.42% agreed that drug design and formulation 
is the key element that influence on the development of monoclonal antibodies. The drug 
design and formulation is the very first stage of developing monoclonal antibodies. For this 
reason, drug development is a critical step as all of the further steps are depending on it, and 
any mistake made at this stage can impact on the whole process. The results indicate that 
there are still gaps by means of managing the molecular attributes of monoclonal antibodies 
to be used for therapeutic purposes, therefore, more research and development studies in the 
field is needed. 
The following two concerns regarding the development were the biodistribution of 
the molecule with 75.71% agreement, and undesirable by products generated during 
manufacture and processing with 71.42% agreement. Because they are biological products, 
both of the biodistribution and manufacturing procedures are dependent to many other 
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metabolic components in the environment which leads to a quite complex procedure overall, 
also difficulties in the prediction of the molecules. 
According to the results in Table 4.9., 85.71% of the medical doctors agreed that 
monoclonal antibodies are safe to use, while 67.14% of the scientists and 
pharmaceutical/biotechnology professionals together formerly stated that there are still 
uncertainties remaining about the safety of monoclonal antibody therapeutics. This conflict 
may have occurred because of the difference of their working areas, as scientists are more 
involved with the research and development, which means a great amount of attempt and 
failure until success, while medical doctors on the other hand, prescribe the already 
authorized monoclonal antibodies which had been tested for numerous times until their 
safety, quality and efficacy are approved and risk/benefit balance is found reasonable. 
When the effectiveness of monoclonal antibodies is evaluated as newly developed 
treatment for diseases on a molecular scale by scientists, the 68.88% scientists agree that 
monoclonal antibodies work well as a newly developed treatment, while from the medical 
doctor’s point of view, they are found 85.71% effective. The statistics indicate that 
monoclonal antibodies show satisfactory outcomes in both research and development and 
medical use. 
Furthermore, among the same group of 66 respondent which consists of scientists and 
medical doctors, 68.18% believed that the benefits of monoclonal antibodies outweigh the 
risks, which shows that scientists and medical doctors are both hopeful for monoclonal 
antibody therapeutics. Additionally, it is another evidence that they are well worth to further 
investigate, and to unravel the existing gaps. 
Results show that the obtained responses regarding the high costs of monoclonal 
antibodies are in parallel with the findings of secondary research, with agreement of 60.20% 
of the total respondents. Even though the majority of the respondents stated that there are 
several governmental funding/support in their country, the specified funding for the research 
and development were comprehensive of all scientific fields, and not specific to monoclonal 
antibodies. There are a few monoclonal antibody therapeutics for the treatment of 
autoimmune disorders and for several cancer types that Turkish Social Security Institution 
(SGK) supports their use. Nevertheless, their supply to pharmacies are limited, and some of 
them are only partially funded (TEB, 2018; SGK, 2018). 
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Even though the regulatory approval procedures of monoclonal antibody therapeutics 
are highly time consuming and consist of many measures and requirements, they are entirely 
focused on the public safety and they cannot be avoided by the pharmaceutical industry. 
According to the outcomes of the Figure 4.11, the national regulatory agencies are deemed 
adequate enough to ensure product efficacy, quality, and patient safety by respondents from 
the USA, Ireland, and India with 71.42% agreement which is a considerably satisfactory 
result overall. 
On the other hand, the same percentage of regulatory professionals also agreed that 
the regulatory differences between countries significantly affect the development/clinical use 
of monoclonal antibodies. Supporting that, as part of the third objective, one of the regulatory 
professionals stated in Table 4.18 that there should be only a single regulatory framework 
which should be adopted globally. This is a significant gap in the global regulatory 
perspective of monoclonal antibody development. To be more specific, if all countries had 
implemented the same regulations, the pharmacovigilance tracking would be much easier, 
and there would be more knowledge available about the use of monoclonal antibodies such 
as the age group or the disease type that it is used for. Additionally, it would also reduce the 
time for various procedures such as market approval, which would also ease the approval of 
biosimilar alternatives that play a key role in cost reduction. 
With the third objective, different perspectives of professionals were aimed to be 
analysed regarding the therapeutic use and challenges of monoclonal antibody therapeutics 
with a qualitative approach. When the received points of views are compared individually 
among professionals, medical doctors had the highest (100%) percentage of positive 
perceptions in the Table 4.17, which is relatively predictable, as it was formerly mentioned 
medical professionals are more involved with the approved therapeutics, therefore, they are 
less exposed to the relatively negative aspects of the molecules. 
Moreover, high costs were the most mentioned concern of the total respondents once 
again. The considerations shared by pharmaceutical/biotechnology professionals in the Table 
4.19 such as biosimilar alternatives, and future advancements in the manufacturing 
technology will be the first steps to overcome those bottlenecks in the development and 
therapeutic use of monoclonal antibodies, especially to minimize cost. In addition to that, it 
is stated in the Table 4.19 that scale-up manufacturing can reduce prices and the 
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biocontamination risk at the same time. This future improvement would also respond to the 
challenge of undesired by products during manufacturing.  
Although there were concerns about the safety and high costs of monoclonal 
antibodies, as well as bottlenecks in the manufacturing due to various factors, the 92.85% of 
the total respondents who agreed that monoclonal antibodies will grow in the future (Table 
4.14), is a great indication that scientists, medical doctors, regulatory professionals and 
pharmaceutical/biotechnology professionals believe that these challenges are achievable and 
will not prevent the growth of monoclonal antibody therapeutics. 
The final objective sought to evaluate their potential for the treatment of COVID-19 
that has recently emerged pandemic. With the ongoing studies and extreme current focus on 
the pandemic worldwide, the research and development in this field have already gained a 
massive speed. In Table 4.16 a very spot-on comment was made by a scientist, stating that 
the research and development of monoclonal antibodies especially for infectious diseases 
will rapidly grow in the near future as a result of COVID-19 pandemic. 
According to the clinical trial results presented in Chapter II, death toll and need for 
intensive care unit among COVID-19 patients were decreased following the exposure to 
tocilizumab which is an excellent progress. Additionally, the 92-year-old man after the 
treatment with levilimab is a great hope for elder patients who are being affected by the virus 
more than any other age group. The advantage of monoclonal antibodies is that they are 
approved therapeutics which have already been used against cytokine storms which are 
present in COVID-19 patients as well. Along with the hopeful outcomes from the ongoing 
clinical trials, and the shorter time needed for developing monoclonal antibodies compared 
to vaccines, as well as their biochemical aspects, monoclonal antibodies show a great promise 
for the treatment of COVID-19. 
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CHAPTER VI: CONCLUSIONS AND RECOMMENDATIONS 
6.1. Research Conclusions 
• The monoclonal antibody discovery has reshaped the research and development 
focus and growth of the pharmaceutical industry with its promising profile for 
currently untreatable diseases, and excessive market demand. 
• The chimerization technology in the generation of monoclonal antibodies helped to 
reduce the safety risks. However, more advanced technologies such as humanization 
of the monoclonal antibodies sourced from different species, or generation of human 
monoclonal antibodies provided a safer use. 
• Implementation of the genetic engineering techniques into monoclonal antibodies 
(i.e. bispecific monoclonal antibodies) fostered the efficacy of the mechanism of 
action. These efforts to generate more human-like, or effective monoclonal 
antibodies also improved the quality of the product. 
• Drug design and formulation is the most challenging factor in the development of 
monoclonal antibodies, due to the complexity of the molecule. Besides bringing the 
challenges in the production of monoclonal antibodies, molecular instability can put 
human health at risk, even may result in mortality. 
• The current technology has not been improved enough to perform a standardized 
mass manufacturing of monoclonal antibodies, resulting in high costs in the 
production. 
• Regulatory differences between countries is a challenge for the advancements in 
monoclonal antibody therapeutics. 
• Monoclonal antibodies show a great hope for many diseases that are currently 
untreatable, and have an extraordinary potential to shape the future of the 
pharmaceutical industry. 
• The ongoing pre-clinical and clinical trials show that monoclonal antibodies have a 
high potential to overcome the recently emerged COVID-19 pandemic. 
6.2. Strategic Conclusions 
• Considering the influential aspects of the monoclonal antibodies within the 
pharmaceutical market profiles, and the rich product pipeline they provide, 
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monoclonal antibodies are well worth to invest in as there are still gaps remaining 
about the biochemical aspects of monoclonal antibodies. 
• The advancements in the formulation of monoclonal antibodies and implementation 
of genetic engineering techniques are likely reduce the safety risks, while increasing 
the efficiency and quality. 
• As experts in this field, the professionals from the pharmaceutical/biotechnology 
industry, scientists, medical doctors, and regulatory professionals are well-aware of 
the risks and challenges that monoclonal antibodies bring. However, they still believe 
that the monoclonal antibodies will shape the future of the pharmaceutical industry, 
which indicates that aforementioned challenges are likely to be manageable in the 
near future.  
• Considering that the availability and effectiveness that monoclonal antibodies show 
in the short-term, they can be very helpful for the patients who are currently suffering 
with COVID-19, especially the ones who are being treated in intensive care unit. 
• Monoclonal antibodies in the COVID-19 treatment is likely to reduce the time needed 
for the treatment, which is precious at the moment. Thus, it can prevent the virus to 
spread and infect more people. 
6.3. Recommendations 
• The studies on the implementation of high-volume manufacturing technologies into 
monoclonal antibodies should be fostered to reduce the manufacturing costs. These 
technology will also help to decrease biocontamination risks, which answers the 
challenge of undesired by products during manufacturing of monoclonal antibodies. 
• The pharmaceutical industry should consistently follow the patent expirations and 
focus on producing biosimilar alternatives to reduce high costs. 
• Governmental supports/funding should be enhanced. Even though there are several 
funding agencies, most of them encourage general scientific research instead of 
research studies specific to monoclonal antibodies (except for unexpected conditions 
such as COVID-19.) 
• The regulations for biological products should be globally standardized. 
• As monoclonal antibodies are promising for the  COVID-19 pandemic with both of 
their biochemical mechanism as well as their aspect to take action in a much shorter 
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term than vaccines, special attention and focus must be provided for the research and 
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Appendix A. The list of monoclonal antibody drugs that approved by major agencies from 
1986 to 2013 (Strohl, 2014). 





























































































































































































































































































































































































Appendix B. The list of monoclonal antibody drugs that approved by FDA from 2013 to 
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Appendix C. A sample of the consent form that was provided to all respondents before their 




This questionnaire is carried out by a student at Griffith College Dublin to identify 
the current challenges in the development and therapeutic use of monoclonal antibodies as 
promising agents in the pharmaceutical industry. 
This is an online questionnaire that will take approximately 4-7 minutes. Your 
participation in this research study is voluntary.  
We will keep your personal data confidential, and the outcomes of this research will 
be used for scholarly purposes only. The name and surname are asked only to ensure the 
information we receive is sourced by experts in the field as this is scientific research and 
appeals only to specific professionals in the biotechnology, pharmaceutical, and health care 
industries. 
Your identification and responses will not be shared with the public. 




Appendix D. A sample of the Section A of the questionnaire that was carried out with 












1. Please describe your level of education.     
Please tick    the appropriate answer: 
☐ Certificate/Diploma  
 
☐ Bachelor’s degree/Advanced diploma  
       
☐ Master’s degree  
 
☐ PhD degree 
 
☐ Other level (please specify)   
 
 
2. Please describe your profession and area of specialty: 
 
 










Please tick the appropriate answer for each question below. 
1. Do you have any involvement/experience/knowledge in the research and 
development and/or production of monoclonal antibodies? 
☐ Yes   
☐ No 




2. Do you agree or disagree with the statement that monoclonal antibodies are 
effective as a newly developed treatment for diseases? 




☐ Strongly disagree 




3. Do you agree or disagree with the statement that the benefits of monoclonal 
antibodies outweigh the risks? 








4. Do you agree that there are certain factors can influence the development 
process of monoclonal antibodies: 
i. Challenges in drug design and formulation  




☐ Strongly disagree 
☐ N/A 
ii. Challenges in chemical structure 




☐ Strongly disagree 
☐ N/A 
iii. Undesirable by products generated during manufacture and processing 




☐ Strongly disagree 
☐ N/A 
iv. Uncertainties about the safety of monoclonal antibody therapeutics 









v. Insufficient knowledge about the effectiveness of monoclonal antibody 
 therapeutics 




☐ Strongly disagree 
☐ N/A 
vi. Challenges in biodistribution of the molecule 




☐ Strongly disagree 
☐ N/A 
5. Is there any governmental research funding/support in your country for the 
development of biologics/monoclonal antibodies? 










6. Do you agree or disagree with the statement that monoclonal antibodies are 
overpriced? 






☐ Strongly disagree 
7. Do you agree or disagree with the statement that the use of monoclonal 
antibodies will grow in the future? 




☐ Strongly disagree 
8. I would be very interested to hear from you if you would like to share any 














Please tick the appropriate box for each question below. 
1. Do you have any experience of treating your patients with monoclonal 
antibodies? 
☐ Yes, please kindly specify the name of the disease and the type of 









2. Do you agree or disagree with the statement that monoclonal antibodies are 
safe to use? 




☐ Strongly disagree 
3. Do you agree or disagree with the statement that monoclonal antibodies are 
effective as a newly developed treatment for diseases? 




☐ Strongly disagree 
90 
 
4. Do you agree or disagree with the statement that the benefits of monoclonal 
antibodies outweigh the risks? 




☐ Strongly disagree 
5. Do you agree or disagree with the statement that monoclonal antibodies are 
overpriced? 




☐ Strongly disagree 
6. Is there any governmental support (i.e. medical card, medical allowance) in 
your country for the use of biologics/monoclonal antibodies? 









7. Do you agree or disagree with the statement that the use of monoclonal 
antibodies will grow in the future? 






☐ Strongly disagree 
8. I would be very interested to hear from you if you would like to share any 













Please tick the appropriate box for each question below. 
1. Do you have any involvement/experience/knowledge in regulatory affairs for 
biologics/monoclonal antibodies? 
☐ Yes   
☐ No 




2. Do you agree or disagree with the statement that the regulations for 
biologics/monoclonal antibodies in your country are adequate enough to 
ensure patient safety, product efficacy and quality? (Please kindly specify your 
country.) 




☐ Strongly disagree 
☐ Other 
 




3. Do you agree or disagree with the statement that regulatory differences 
between countries have a significant impact on the development/clinical use of 
monoclonal antibodies?  






☐ Strongly disagree 





4. Do you agree or disagree with the statement that monoclonal antibodies are 
overpriced? 




☐ Strongly disagree 
5. Is there any governmental research funding/support in your country for 
development of biologics/monoclonal antibodies? 










6. Do you agree or disagree with the statement that the use of monoclonal 
antibodies will grow in the future? 






☐ Strongly disagree 
7. I would be very interested to hear from you if you would like to share any 
additional information, thoughts or experience of working with the regulatory 







Appendix H. A sample of the Section B of the questionnaire that was carried out with 
professionals working in the pharmaceutical/biotechnology industry. 
SECTION B 
PROFESSIONALS WORKING IN THE 
PHARMACEUTICAL/BIOTECHNOLOGY INDUSTRY 
Please tick the appropriate box for each question below. 
1. Do you have any experience of working with biologics/monoclonal antibodies?  
☐ Yes 
☐ No 




2. Do you agree that there are certain factors that can influence the 
development process of monoclonal antibodies: 
i. Challenges in drug design and formulation  




☐ Strongly disagree 
☐ N/A 
ii. Challenges in chemical structure 









iii. Undesirable by products generated during manufacture and processing 




☐ Strongly disagree 
☐ N/A 
iv. Uncertainties about the safety of monoclonal antibody therapeutics 




☐ Strongly disagree 
☐ N/A 
v. Insufficient knowledge about the effectiveness of monoclonal antibody 
 therapeutics 




☐ Strongly disagree 
☐ N/A 
vi. Challenges in biodistribution of the molecule 









3. Is there any governmental research funding/support in your country for the 
development of biologics/monoclonal antibodies? 










4. Do you agree or disagree with the statement that monoclonal antibodies are 
overpriced? 




☐ Strongly disagree 
8. Do you agree or disagree with the statement that the use of monoclonal 
antibodies will grow in the future? 




☐ Strongly disagree 
5. I would be very interested to hear from you if you would like to share any 
additional information, thoughts or experience about monoclonal antibodies: 
 
 
 
